Official Title: A Pilot Placebo -controlled Human Laboratory Feasibility Study of 
Lacosamide Effects in Alcohol Use Disorder  
 
NCT number: [STUDY_ID_REMOVED]  
 
Document date: 03/13/2019  
Department of Veterans Affairs INFORMED CONSENT FORM
Subject Name:  Date:
Title of Study:  A PILOT PLACEBO-CONTROLLED HUMAN LABORATORY FEASIBILITY STUDY OF 
LACOSAMIDE EFFECTS IN ALCOHOL USE DISORDER
Principal Investigator:  STEVEN L. BATKI, MDSAN FRANCISCO VAMC
02/06/19
VA 10-1086Page 1 of 16 ACGT
This is a medical research study funded by UCSF‚Äôs Alcohol Center for Genes and Translation (ACGT). The 
principal investigator (PI) is Steven L. Batki, MD from the San Francisco VA Medical Center and the UCSF Department of Psychiatry.  One of the study staff, supervised by the PI, will explain the study to you. 
You are being invited to take part in this study because you have indicated that you are drinking alcohol 
at levels or in a manner that may harmful to your health (you meet diagnostic criteria for alcohol use disorder) and you have indicated that 
you are not interested in seeking treatment to reduce your alcohol 
use.
The purpose of this form is to give you information about the study. This form describes the purpose, procedures, benefits, risks, discomforts and precautions of the study.  You should take part in the study only if you want to. Signing this form will give your permission to take part in the study. You may decide not to join the study. It is important to know that if you start the study, you may leave at any time. There is no penalty for leaving and you will not lose any benefits to which you are otherwise entitled.   Some risks of this study are known; not all possible risks are known. 
1. Why is this study being done?
The purpose of this study is to discover how the medication lacosamide affects a person‚Äôs use of alcohol and other alcohol related behavioral measures.  Lacosamide, marketed under the brand name Vimpat¬Æ, is an FDA approved medication for treating epilepsy. There is some preliminary evidence from research using animals that a single dose of lacosamide might reduce alcohol craving and/or consumption. 
Lacosamide has not been proven safe or helpful by the US Food and Drug Administration (FDA) for the 
treatment of alcoholism. 
The PI and other study staff in this study do not have a financial interest in the company that 
manufactures lacosamide. 
2. How many people will take part in this study?
About 4-6 men will be enrolled in this study. 
3. Are there some people who should not be in this study?
The study doctor or a member of the study staff will talk with you about the requirements to be in this study. It is important that you are truthful with them about your history. You should not be in this study if you do not meet all the qualifications. 
	








02/06/19
VA 10-1086Page 2 of 16 ACGTYou should not be in this study if:
ÔÇ∑You are currently receiving lacosamide or other medication for alcoholism, including disulfiram 
(Antabuse), naltrexone (Depade, Revia or Vivitrol), or acamprosate (Campral).
ÔÇ∑You are younger than 18 years old or older than 50 years of age.
ÔÇ∑You are seeking treatment for alcoholism, or if you would like to receive treatment to help reduce alcohol use.
ÔÇ∑You are currently receiving treatment for alcoholism, or have received treatment for alcoholism in the past 6 months.
ÔÇ∑You are already in another alcohol treatment study or study involving medication as a treatment for alcohol use.
ÔÇ∑You have liver disease, heart disease, pancreas problems, diabetes, neurological problems, or if you have gastrointestinal problems that are worsened by drinking alcohol.
ÔÇ∑You are taking medications that may have bad interactions with the study medication, lacosamide (the study doctor will ask check this).
ÔÇ∑You regularly used in the past 30 days opioids, cocaine, benzodiazepines, or barbiturates.
ÔÇ∑You regularly used in the past 30 days medications that can affect your brain and nervous system such as medicines used to treat psychiatric conditions like psychosis, anxiety, depression, or medications to treat epilepsy (seizures).
4. How long will I be in the study?In total, you would be asked to commit approximately 40 hours of your time over the course of 7 weeks.
5. What will happen if I take part in this research study?
All study procedures will take place at the San Francisco VA Medical Center. The study can be divided into the 3 parts:
a. Screening: 1-3 visits over approximately 1 week
b. Main part: 3 visits over 5 weeks to complete 3 all-day Alcohol Drinking Paradigm (ADP) sessions
These 3 all-day ADP sessions will be at the San Francisco VA Medical Center. At each of these 3 all-day 
study visits, you will participate in an alcohol drinking session under observed conditions. We refer to each of these all-day sessions as an Alcohol Drinking Paradigm (ADP).  
At each of these 3 ADP sessions, you will be asked to take study medication and then you will be offered 
alcoholic beverages, mixed with fruit juice, and allowed to drink them within a certain period of time, under observed conditions. Study staff will be measuring how much alcohol you consume at each of these 3 ADP sessions. Each ADP session starts at 8am and finishes around 8pm, for a total of 12 hours. 
c. Follow-up: 1 visit 7 days after the last ADP
5a. During the screening part of the study
To see if you are eligible to participate in the study, we will ask that you take part in the following exams, tests and procedures.   Information will be kept confidential (as detailed later in this Consent Form).
	








02/06/19
VA 10-1086Page 3 of 16 ACGTBreath alcohol test + informed consent : 
The study will be discussed with you, and you will be asked to sign this consent form after you blow a 
0.00 on your breath alcohol test.  If you have ANY alcohol on your breath, as measured by the breathalyzer, you will be asked to wait until you have no alcohol on your breath or to complete your visit at another time.
ÔÇ∑You can also ask to be referred to other treatment if you wish.
ÔÇ∑If you are legally intoxicated, you will be offered transportation home.
Contact information : 
You will be asked to provide the names and phone numbers of people we may contact in case you miss a study appointment. Research staff will confirm your personal contact information, as well as that of your alternate contact, before you can continue in the study.
Medical history and physical exam : 
The study doctor will take your medical history and review the medication you use. You will also have a brief physical examination. The history and physical exam are similar to those done for regular medical care. 
Vital signs : 
A study staff member will measure your blood pressure, heart rate, height and weight. 
Concomitant medication : 
A study doctor will review all the other medications you are currently taking to make sure it is safe for you to take the study medication, lacosamide.
Electrocardiogram (ECG) : 
A study nurse will conduct an electrocardiogram (ECG or EKG) to check the health of your heart to make sure it is safe for you to participate in the research study.
Blood drawing (venipuncture) : 
You will be asked to give a blood sample for routine laboratory tests to check your health.  Approximately 2 teaspoons of blood (8 ml) will be drawn by inserting a needle into a vein in your arm for these tests. Blood will be taken for routine medical tests. 
Urine sample : 
You will be asked to give a urine sample to test for drug use, including recreational and illegal drugs and alcohol. 
Medical and psychiatric diagnoses : 
You will be evaluated for current and previous diagnoses.
Substance use assessments : You will be asked to report your use of alcohol and other substances 
(cigarettes, marijuana, cocaine, etc.)
	








02/06/19
VA 10-1086Page 4 of 16 ACGTQuestionnaires : You will be asked to complete questionnaires about your education, work, and other 
aspects of life. Some of the questionnaires ask that you answer detailed questions about your alcohol 
use, alcohol craving and family history of alcohol use. 
Cognitive testing : 
Your cognition (ability to think) will be measured through a serious of tests. We will continue to administer these tests throughout the study so that we can try to understand how alcohol use and/or the study medication, lacosamide, affects your thinking. 
5b. During the main part of the study
After the screening tests have been reviewed by the study doctor, and you continue to meet eligibility requirements, you will begin the main part of the study. 
Overview : 
You will be asked to attend 3 all-day study visits at the San Francisco VA Medical Center for the main part of the study. At each of these 3 all-day study visits, you will participate in an alcohol drinking session under observed conditions. We refer to each of these all-day sessions as an Alcohol Drinking Paradigm (ADP).  
At each of these 3 ADP sessions, you will be asked to take study medication and then you will be offered 
alcoholic beverages, mixed with fruit juice, and allowed to drink them within a certain period of time, under observed conditions. Study staff will be measuring how much alcohol you consume at each of these 3 ADP sessions. Each ADP session starts at 8am and finishes around 8pm, for a total of 12 hours. 
Details : 
We ask that you not consume alcohol after 5 pm on the evening prior to each ADP session. When you 
arrive at the San Francisco VA Medical Center (SFVAMC), we will monitor your breath alcohol level by asking you to blow into the breathalyzer. If you arrive with a positive breath alcohol level and your breath alcohol level is above 0.05 and/or is increasing, indicating recent alcohol consumption, then the session will have to be rescheduled. If your breath alcohol level is less than 0.05 and is decreasing, we will have to wait until it comes down to 0 before conducting any assessments. If your breath alcohol level is above 0.05 and the session has to be rescheduled, we will have to keep you at the SFVAMC and advise you not to drive until it comes down to 0.02. Alternatively, we could provide you with transportation. 
We will also collect a urine sample to screen for the use of drugs (e.g. cocaine, opiates, 
benzodiazepines). This test will have to be negative, except for marijuana, for you to continue in the study. 
Once you are settled in the room where the study visit will be conducted, you will be asked to take  
study capsules. At each ADP session, you will receive different study capsules, either 100 mg of lacosamide, 200 mg of lacosamide or placebo. Neither you nor the study staff will not know which capsules you are being asked to take. The only person who knows is the San Francisco VA Research Pharmacist. 
After medication, we measure your height and weight, your heart rate and blood pressure, and ask you 
to complete some assessments and computer tasks. You will be given a light breakfast around 9:00 am, 
	








02/06/19
VA 10-1086Page 5 of 16 ACGTand a late lunch/early dinner around 3:30pm. If you are a smoker, you will be provided with 2 ‚Äúsmoke-
breaks‚Äù during which you will be escorted out and allowed to smoke up to 2 cigarettes. Non-smokers will also be given the option of taking ‚Äòbreaks‚Äô at certain intervals. When you are not completing assessments, you will be able to relax, read a book or be on your cell phone.
Later that same day, you will participate in the ADP. A video camera will be recording this session to 
monitor your drinking behavior.  Prior to the start of this session, you will be asked to complete some questionnaires and rating scales. We will test your breath alcohol level over the course of the ADP and we will test your blood alcohol level once during the ADP. To test your blood alcohol level, approximately 1/2 a teaspoon of blood (3 ml) will be drawn by inserting a needle into a vein in your arm for these tests.
At 12 noon, you will be provided with your first alcohol drink. The alcohol content of this drink will vary 
according to your weight and will be equivalent to one typical mixed drink. You will be asked to drink it in 5 minutes. You must consume this drink in order to remain in the study.  If you do not wish to consume the drink, you will be discharged from the study.  You will then be monitored for the next 55 minutes and asked to complete assessments. 
At 1:00 pm you will be presented with 4 drinks, each of which we consider to be worth $3, for a total of 
$12. During the next 50 minutes, you can either choose to drink or keep the money value of the drinks ($3 per each drink that you do not drink).  If you choose the money, it will be given to you after the session is completed.  
At 1:50 pm, the old drinks will be removed.At 2:00 pm you will be presented with 4 fresh, new drinks, each worth $3. These will be available to you 
for the next 50 minutes. Again, you can choose to drink them or keep the money. The drinks will be removed at 2:50 pm at which time the ADP session is over. Your breath alcohol level, blood pressure and heart rate will be monitored until your breath alcohol level returns to 0.02. You will also be asked to complete various assessments during the remainder of your stay.  
At 8:00 pm you will be discharged and paid in return for your time and effort. If your breath alcohol level 
is above 0.02 at 8:00 pm, then a study doctor will conduct a brief examination to make sure it is safe for you to go home. If in the judgment of the study physician you are too intoxicated to safely go home, you will be taken to SF VA Emergency Department by the study physician for further evaluation and treatment, if needed.
The following day, a member of the study team will check in with you by phone to assess for any side 
effects.
You will repeat the ADP sessions on 2 more days, for a total of 3 ADP sessions.  There will be 7 days 
between the 1
st and 2nd ADP session and 7 days between the 2nd and 3rd ADP session. All ADP sessions 
are identical in nature, except for the study medication given to you when you arrive.
	








02/06/19
VA 10-1086Page 6 of 16 ACGTIt is important to note that during the ADP sessions phone use, watching TV, and sleep will be restricted 
as follows:
TIME PHONE USE TV SLEEP
8:30 AM ‚Äì 9:30 AM NO NO NO
9:30 AM ‚Äì 10:00 AM YES NO NO
10:00 AM ‚Äì 11:00 AM NO NO NO
11:00 AM ‚Äì 11:30 AM YES NO NO
11:30 AM ‚Äì 3:00 PM NO NO NO
3:00 PM ‚Äì 8:00 PM YES YES NO
5c. During the follow-up part of the studyThere is 1 follow-up visit ‚Äì 1 week after you 3
rd and final ADP session. 
Follow-up visit at 1 week : 
You will be asked to describe any emotional side effects you may have experienced since the last study visit. A psychiatrist or psychologist will talk to you about your drinking behavior, and if you are interested, will provide you with treatment referrals. This appointment will be conducted with all participants, even those who do not complete the entire study, and will take approximately 1 hour.
5d. Study Plan
Another way to find out what will happen to you during the study is to read the chart below. Start reading on the left side of the paper, and following the lines and arrows.
Consent & 
Screening 
Visit(s)
Randomization Lacosamide 100 mg Lacosamide 200 mg1st Human Lab Session1st Human Lab Session
7 day washout 
no medication7 day washout 
no medication1 Week 
Follow-Up2nd Human Lab Session2nd Human Lab Session
Lacosamide 100 mg Lacosamide 200 mg
Lacosamide 200 mg Lacosamide 100 mg PlaceboPlaceboPlacebo
7 day washout 
no medication7 day washout 
no medication3rd Human Lab Session3rd Human Lab Session
	








02/06/19
VA 10-1086Page 7 of 16 ACGT6. How long will I be in the study?
The study is 7 weeks in total. There are only 5 visits over the course of 7 weeks.  Please refer to the Study Visit Schedule below.
Study Visit Schedule
WEEK STUDY VISIT AMOUNT OF TIME PER VISIT (approximate)
Week 1 Screening visit 3 hours*
ADP session #1 12 hoursWeek 2 Follow-up phone visit #1 10 minutes
Week 3 No visits
ADP session #2 12 hoursWeek 4Follow-up phone visit #2 10 minutes
Week 5 No visits
ADP session #3 12 hoursWeek 6Follow-up phone visit #3 10 minutes
Week 7 Follow-up visit @ 1 week 1 hour*
TOTAL5 (in-person) STUDY 
VISITSAPPROXIMATELY 40 HOURS AND 30 
MINUTES
*The amount of time is an approximation
7. Can I stop being in the study?Yes. You can decide to stop at any time. Tell the study doctor if you are thinking about stopping or decide to stop. He or she will tell you how to stop your participation safely. 
It is important to tell the study doctor if you are thinking about stopping so any risks from the 
lacosamide can be evaluated by your doctor. Another reason to tell your doctor that you are thinking about stopping is to discuss what follow-up care and testing could be most helpful for you.
The study doctor may stop you from taking part in this study at any time if he believes it is in your best 
interest, if you do not follow the study rules, or if the study is stopped.
8. What side effects or risks can I expect from being in the study?
The study visits and procedures are designed to limit risks to your health and limit your discomfort as much as possible. These procedures closely monitor your safety throughout the study.
You may have side effects while in the study. Everyone taking part in the study will be watched carefully 
for any side effects. However, doctors don't know all the side effects that may happen.  Side effects may be mild or very serious. Your health care team may give you medicines to help lessen side effects. Many side effects go away soon after you stop taking the lacosamide
. In some cases, side effects can be 
serious, long lasting, or may never go away. You should talk to your study doctor about any side effects you experience while taking part in the study.
	








02/06/19
VA 10-1086Page 8 of 16 ACGTBelow, we have listed side effects that have been known to occur when lacosamide is administered up to 
200 mg as treatment for epilepsy. The maximum dose you would receive in this study is 200 mg:
Less Likely (less than or equal to 20% of patients)
ÔÇ∑Dizziness (16%)
ÔÇ∑Headache (11%)
ÔÇ∑Nausea (7%)
ÔÇ∑Fatigue (7%)
ÔÇ∑Vomiting (6%)
ÔÇ∑Double vision (6%)
ÔÇ∑Sensation of spinning (vertigo) (5%)
ÔÇ∑Sleepiness (5%)
ÔÇ∑Tremor (4%)
ÔÇ∑Loss of coordination of muscle movements (ataxia) (4%)
Rare but serious
ÔÇ∑Suicidality: Like other epilepsy treatment medicines, lacosamide may very rarely cause suicidal 
thoughts or actions in a very small number of people, about 1 in 500. 
ÔÇ∑Abnormal heartbeat: In less than 1% of patients lacosamide could cause abnormal heart rhythm.
Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse or worry you: thoughts about suicide or dying, attempts to commit suicide, new or worse depression, new or worse anxiety, feeling agitated or restless, panic attacks, trouble sleeping (insomnia), new or worse irritability, acting aggressive, being angry, or violent, acting on dangerous impulses, an extreme increase in activity and talking (mania), other unusual changes in behavior or mood. 
Risks associated with lacosamide and alcohol: 
There are no published reports about combining lacosamide and alcohol. There may be added effects from combining lacosamide with alcohol. Possible risks include sedation and trouble with thinking or coordination that could persist for several hours after last alcohol drinking (3:00 pm ‚Äì 4:00 pm). It is expected that alcohol effects will wear off in the ensuing 4 hours before discharge from the CRC at 8:00 pm.
Risks associated with lacosamide and other medications:
Lacosamide may cause a change (increase or decrease) in the effect of some other medications.  If you are taking other medications during your participation in this study, immediately inform study staff.  The study doctor will review any medications that you are talking and make the determination as to whether continued study participation is safe for you.
Risks associated with alcohol: 
A number of medical conditions could potentially be worsened by acute alcohol administration, such as liver disease, heart disease, pancreas problems, diabetes, neurological problems, or gastrointestinal problems.  If you have any of these medical problems, you should not participate in this study. Alcohol may also cause nausea in high doses; however, nausea is not expected at the dose being used in this study. In order to ensure that you do not fall and hurt yourself after consuming alcohol, we will ask you to stay at the SF VA Medical Center until your breath alcohol level returns to 0.02 or less. Alcohol can be 
	








02/06/19
VA 10-1086Page 9 of 16 ACGTaddictive. We do not recommend that you continue drinking alcohol in the quantities that will be used in 
this research study.
Risks associated with alcohol withdrawal : 
We are not going to ask you to change your drinking behavior while you are participating in this study. However, you should know that some individuals who suddenly reduce or stop their drinking can experience alcohol withdrawal symptoms such as nervousness, shaking, loss of appetite, difficulty sleeping or more severe symptoms like extreme restlessness, confusion, hallucinations (hearing and seeing things that are not there) and seizures -- but these are extremely rare. We will monitor you very closely for withdrawal symptoms during your daily visits to our clinic. If you experience worsening of withdrawal symptoms, you may have to be hospitalized and will be given the standard medications that are used to treat and manage withdrawal. 
Blood drawing (venipuncture) risks : Drawing blood may cause temporary discomfort from the needle 
stick, bruising, infection and fainting. We expect to draw 17 mL amount of blood (about 3.5 teaspoons) over the course of the study.
STUDY VISIT AMOUNT OF BLOOD
Screening 8 mL or 2 tsp
1st ADP session 3 mL or ¬Ω tsp
2nd ADP session 3 mL or ¬Ω tsp
3rd ADP session 3 mL or ¬Ω tsp
TOTAL 17 mL or 3.5 tsp
Risk of distress/fatigue due to psychiatric and other assessments:  
Risks related to answering questions about your medical/psychiatric history, reporting of drug use, taking part in assessments of your thinking may include fatigue and distress. You are free to decline to answer any questions or to stop assessments at any time. Assessments and interviews will include breaks. If you are uncomfortable, let us know and the session will be immediately discontinued.
Reproductive risks : 
You should not father a baby while on this study because the drugs in this study can affect an unborn baby. It is important to understand that you need to use birth control while on this study. Check with your study doctor about what kind of birth control methods to use and how long to use them. Some methods might not be approved for use in this study.
Unknown risks : 
The study medicine may have side effects that no one knows about yet. The researchers will let you know if they learn anything that might make you change your mind about participating in the study.
For more information about risks and side effects, ask your study doctor. 9. Are there benefits to taking part in the study?
There will be no direct benefit to you from participating in this study.  However, this study will help doctors learn more about  lacosamide and whether it can help treat alcoholism, and it is hoped that this 
information will help in the treatment of future patients with a desire to reduce alcohol use.
	








02/06/19
VA 10-1086Page 10 of 16 ACGT10. What other choices do I have if I do not take part in this study?
You do not have to be in this study. 
You may choose to seek treatment services.You can obtain FDA-approved medications for alcoholism through your general medical care provider. 
You are free to seek treatment through your general care providers. 
You may also choose not to seek treatment for your use of alcohol.11. How will information about me be kept confidential?
Participation in research involves some loss of privacy. We will do our best to make sure that informationabout you is kept confidential, but we cannot guarantee total privacy. Some information from yourmedical records will be collected and used for this study. If you do not have a San Francisco VA MedicalCenter medical record already, one will be created for you by the study staff.
The information that will be collected includes demographic information (for example: name, address,
age, date of birth, social security number) and health information (psychiatric information, alcohol anddrug use, and medical information). By signing this form, you are giving the study staff permission to use the information collected about your health (medical, mental health, alcohol and other substance use). This authorization to access and use the information will not expire. You have the right, at any time, to take back your authorization and end the study staff‚Äôs access to your personal information.
Every effort will be made to protect the confidential nature of your identifying information by assigning
you a unique identification code during the study. All information and data collected by the study staffduring this study will contain this identification code instead of any identifying personal information. Thisidentification code will be stored in an electronic database on a password-protected, secure web servermanaged through the SFVAMC. The data manager will download study data from the server that will beneeded for analysis and store it in a password-protected database, stored on a VA server behind asecure VA firewall at the SFAVMC. The written log that connects your identification code to thedemographic information you give us will be kept in a file separate from the collected data. This log willhave restricted access and will be stored in locked cabinets when not in use. Any data sent via emailmessages or delivery service will be encrypted and password-protected.
Video recordings will be stored on a password-protected, secure web server managed through the 
SFVAMC and will not be deleted in accordance with VA research rules. 
To ensure your safety and the safety of others, information may be shared between research staff and 
your clinical team only under the following circumstances: 1) If in the judgment of the study physician, you have a psychiatric or medical condition that requires urgent attention to protect your safety and that of others; and 2) If you have missed several study appointments, and research staff needs to verify your whereabouts and/or verify your safety.
Progress notes will be added to your medical record, which indicate your participation in the study and 
that you will be taking the study medication and consuming alcohol in the laboratory setting, and the name and contact information for the investigator conducting the study. Details like urine drug test results, the study name or number will not be included in the progress notes.  
	








02/06/19
VA 10-1086Page 11 of 16 ACGTStudy tests that are performed by non-VA research labs and information gathered directly from you by
the study staff will be part of your research study records but will not be added to your medical record.Your personal information may be given out if required by law. If information from this study is published or presented at scientific meetings, your name and other personal information will not be used.
There are several regulatory organizations that may look at and/or copy your research and medical
records for research, quality assurance, and data analysis. These organizations include:
oMembers of the study‚Äôs Data and Safety and Monitoring Board
oAlcohol Center for Genes and Translation (ACGT)
oUniversity of California, San Francisco Institutional Review Board (UCSF IRB)
oThe Food and Drug Administration (FDA)
oDepartment of Veterans Affairs
oOffice for Human Research Protections (OHRP)
In this study, you will be asked questions about illegal drug use and your urine will be testedfor illegal drugs. The researchers will keep information about you as confidential as possible, butcomplete confidentiality cannot be guaranteed. On rare occasions, research records have beensubpoenaed by a court.
12. Will any research-related procedures be billed to me? 
No. There will be no direct costs to you if you take part in this study. The study will pay for the medication and study procedures (for example: blood tests). Study participation will be free to you. You may need to pay an indirect cost of transportation to the San Francisco VA Medical Center in order to complete study visits.
13. Will I be paid for taking part in this study?You will be paid in cash for all screening measures completed, with the potential to earn up to $85.
For ADP Sessions 1, 2 and 3, you have the potential to earn up to $224 per visit. You will be paid $200 
by check for each of the 3 completed ADP Sessions.  The check will be issued by UCSF and mailed to the 
address you provide, and should be received within 2 weeks  after your visit. 
Depending on how many drinks you consume per session, you could receive up to $24  in cash per 
ADP session**. This cash payment will be issued at the end of each drinking session. 
You will also receive $25 in cash for attending the follow-up visit 1 week after the 3rd and final ADP 
session.If you attend all 3 ADP sessions, plus the final follow-up visit, then you will receive an additional $50 in 
cash at the follow-up visit.
	








02/06/19
VA 10-1086Page 12 of 16 ACGTIn summary:
WEEK ATTEND STUDY VISIT ATTEND ALL SESSIONS TOTAL PER 
VISIT
Screening $85* $85
ADP Session #1 $200 (+ up to $24)** $224
ADP Session #2 $200 (+up to $24)** $224
ADP Session #3 $200 (+up to $24)** $224
Follow-up @ 1 Week $25 $50 if attend 3 ADP sessions*** $75
POTENTIAL TOTAL AMOUNT PAID $832
*Payment for screening visits depends on the completion of tasks at each visit. You will earn up to $85 
total if you complete all screening measures. 
**Please note that you could earn up to $24 per ADP session, depending on how many drinks you 
consume per session. At each session, you will be offered 8 drinks, each worth $3. You will receive $3 for each drink not consumed. 
***If you attend all possible study visits, you will receive an extra $50 at the last study visit. Because this study offers participants total payments equal or greater than $600 in a calendar year 
period, then the payments are considered tax reportable income. This means that we will share your home address and Social Security Number with the Accounts Payable Manager, using a secured file via email. You will also be asked to fill out a W-9 form. 
14. What happens if I am injured because I took part in this study?
It is important that you tell your study doctor, Steven L. Batki, MD, if you feel that you have been injured because of taking part in this study. You can tell the doctor in person or call him at 415-221-4810 x 23671.
Treatment and Compensation for Injury: If you are experiencing a medical emergency, please call 9-1-1. If you incur an injury or illness as a result of being in this study, the Department of Veterans Affairs (VA) will ensure that treatment is made available at a VA medical facility or non-VA facility, as appropriate. If you were following study instructions, the costs of such treatment will be covered by the VA or the study sponsor (if applicable). If you were NOT following study instructions, the costs of such treatment may be covered by the VA or the study sponsor (if applicable), or may be billed to you or your insurer just like any other medical costs, 
	








02/06/19
VA 10-1086Page 13 of 16 ACGTdepending on a number of factors. The VA and a study sponsor do not normally provide any 
other form of compensation for injury or illness. For further information about this, call the study team at the number(s) provided. 
15. What are my rights if I take part in this study?Taking part in this study is your choice. You may choose either to take part or not to take part in the study. If you decide to take part in this study, you may leave the study at any time. No matter what decision you make, there will be no penalty to you and you will not lose any of your regular benefits. Leaving the study will not affect your medical care. You can still get your medical care from our institution. 
We will tell you about new information or changes in the study that may affect your health or your 
willingness to continue in the study.
In the case of injury resulting from this study, you do not lose any of your legal rights to seek payment 
by signing this form.
16. What are my responsibilities as a study participant?
ÔÇ∑As a participant in this study, your responsibilities are as follows:
Following the instructions given to you by the study staff and study doctor.
ÔÇ∑Attending all study visits as scheduled.
ÔÇ∑Communicating with study staff if you will not be able to attend a study visit as scheduled.
ÔÇ∑Reporting any side effects, injuries, or other changes in your health to the study doctor.
ÔÇ∑Reporting all medicines, vitamins, recreational drugs, herbal products, supplements, or over-the-counter products you use during the study.
ÔÇ∑Speaking with the study doctor if you would like to stop participation in the study.
IMPORTANT: We request that you abstain from driving to the VA Medical Center for study visits if you have been drinking. If you do drive and your breath alcohol level is above a 0.08, then a clinician will assess your safety before you will be allowed to leave. This is a VA protocol established to ensure your safety.
NEW INFORMATION ABOUT THE STUDY DRUG: If important or new information about the study 
drug (good or bad) is learned while you are in the study, you will be told. You will be asked for your consent to continue in the study with the new information. You are free to leave the study at any time without penalty.
17. Clinical Trial Registry Data Bank
A description of this clinical trial will be available on http://www.ClinicalTrials.gov as required by U.S. 
Law. This web site will not include information that can identify you. At most, the web site will include a summary of the results. You can search this web site at any time.
18. Who can answer my questions about the study?
You can talk to your study doctor about any questions or concerns you have about this study. At the San Francisco VA, please contact you study doctor, Steven L. Batki, M.D. at 415-221-4810 x 23671 or page him at 415-313-6537.
	








02/06/19
VA 10-1086Page 14 of 16 ACGTFor questions about your rights while taking part in this study, call the office of the Committee 
on Human Research, UCSF‚Äôs Institutional Review Board (a group of people who review the research to 
protect your rights) at 415-476-1814.
	








02/06/19
VA 10-1086Page 15 of 16 ACGTCONSENT OF RESEARCH PARTICIPANT
You have been given copies of this consent form and the Experimental Participant‚Äôs Bill of Rights to 
keep.
You will be asked to sign a separate form authorizing access, use, creation, or disclosure of health 
information about you.
PARTICIPATION IN RESEARCH IS VOLUNTARY . You have the right to decline to participate or to 
withdraw at any point in this study without penalty or loss of benefits to which you are otherwise 
entitled. 
Optional Procedures: Please indicate if you agree to participate in the following optional procedure by 
placing your initials on one of the lines below
-----------------------------------------------------------------------------------------------------------
__________ I agree to be contacted after this study is done and/or to be asked to be in other studies.__________ I do not agree to be contacted after this study is done or to be asked to be in other studies.-----------------------------------------------------------------------------------------------------------
If you wish to participate in this study, you should sign below.
Signature of Participant Date
__________________________________________________
Printed Name of Participant
Signature of Person Obtaining Consent Date
__________________________________________________Printed Name of Person Obtaining Consent
	








02/06/19
VA 10-1086Page 16 of 16 ACGT
	








1¬†
¬†PROTOCOL VERSION 3/08-1-18 
 
 
FILE NAME ACGT Protocol 
 
STUDY TITLE A Pilot Placebo-Controlled Human Laboratory Feasibility Study of Lacosamide Effects in Alcohol Use Disorder 
 
STUDY NUMBER 17-22190 
 
CLINICAL PHASE Phase 2 
 
    
 
  
2¬†
¬†1. INTRODUCTION 
This document is a protocol for a human research study. The purp ose of this protocol is to ensure that this study is to be 
conducted according to ICH GCP guidelines (CRF 21 Part 312), applicable government regulations and Institutional 
research policies and procedures. 
 
2. BACKGROUND  2.1 Background Prevalence of Research Topic 
AUD is difficult to treat, and currently available medications are underutilized, due at least in part to their limited 
effectiveness [1-3]. There is a critical ne ed for more efficacious medications for AUD.  Preclinical rodent work from ACGT 
investigator Dr. Dorit Ron has identified a specific molecular target that promotes exce ssive alcohol intake. Dr. Ron 
discovered that collapsin response mediator protein-2 (CRMP-2)  [4], a downstream mediator of mammalian target of 
rapamycin complex 1 (mTORC1)  signaling [4-8], is critical for pr omoting excessive alcohol intake [4]. 
 
The central goal of this pilot project  is to lay down the groundwork necessary for the later conduct of more definitive 
studies designed to translate the ACTG‚Äôs basic science discoveries into human trials of novel pharmacotherapies for AUD.  
The FDA-approved anticonvulsant, lacosamide [13,38- 40] inhibits CRMP-2 [4,12,13]. We will conduct the  first pilot 
laboratory clinical trial of lacosamide  in humans with AUD. The ultimate goal  of this proposal is that this medication can 
be repurposed for the treatment of AUD if it is safe and feasib le to use in future larger st udies that will test its ability to  
reduce alcohol drinking and behavioral biases for alcohol in heavy drinkers with AUD. 
 
2.2 Prior Experience 
 2.2.1 Preclinical Experience 
CRMP-2 as a novel molecula r target for AUD treatment : Studies from Dr. Ron‚Äôs groups es tablished that alcohol exposure 
activates mTORC1 in specific brain regions in rodent, an d that mTORC1-related signaling is centrally important for 
promoting excessive alcohol drinking [4-8]. mTORC1 acts by incr easing translation of synaptic plasticity proteins [48], and 
recent work by Dr. Ron‚Äôs group identified one of these proteins , CRMP-2, as critical for promoting excessive alcohol intake 
[4]. CRMP-2 is a microtubule-binding protein that regulate s synaptic structure [4,12,13], and alcohol drinking increases 
CRMP-2 and microtubule assembly [4]. Importantly, inhi bition of CRMP-2 with systemic administration of lacosamide , an 
FDA-approved small molecule inhibitor of CRMP-2 [4,12,13], si gnificantly reduces excessive alcohol intake without altering 
sucrose intake, open field locomotion or anxiety [4], suggest ing that lacosamide does not have more general motor or 
motivational effects. These exciting findi ngs implicate lacosamide, which is availa ble as the FDA-approved anticonvulsant 
Vimpat¬Æ, as a novel treatment for AUD.   2.2.2 Clinical Experience 
Assessing lacosamide effects on alcohol drinking, impulsivity, craving, and approa ch bias: We will conduct the first human 
tests of the efficacy of lacosamide to reduce alcohol drinkin g in non-treatment-seeking hea vy drinkers with AUD, using 
the Yale Alcohol Drinking Paradigm (ADP).  The ADP is also referred to as the ‚ÄúO‚ÄôMalley Choice Against Money Paradigm‚Äù 
in a recent review by Bujarski and Ray [100], who state that the ADP is the more widely used of the two main categories 
of current oral alcohol-self administration methods. Dr. Kri shnan-Sarin at Yale University helped to develop the ADP, 
which has been adopted by a number of in vestigators [16-27], since it has proven highly reliable in measuring medication 
effects on intake. In addition to alcohol intake, we will  also assess whether the test medications are able to reduce 
neurobehavioral vulnerabilities  such as craving, impulsivity, and alcohol approach bias , that are known to promote heavy 
alcohol drinking [1,28-34]. We propose to employ measures that  are widely used and well-validated. Significant effects by 
the test medications would indicate that CRMP-2 and/or OXR are also critical to promoting the neurobehavioral 
vulnerabilities that promote drinking.   
3. RATIONAL SIGNIFICANCE  
3.1 Problem Statement 
Based on findings discussed above, the premise of this work is that (1) molecular mechanisms that drive excessive 
alcohol intake in rodents can also promote heavy drinking in humans with AUD, that (2) the use of lacosamide, to inhibit 
CRMP-2 [4,12,13], for reducing human drinking is supported by  rodent studies from ACGT researchers and that (3) the 
Alcohol Drinking Paradigm and the proposed measures of neurobehavioral contributors to alcohol drinking are well-
validated and are drivers of alcohol use by heavy drinkers with  AUD in human laboratory studies; and that (4) lacosamide 
may represent a novel and potent pharmacotherapy to treat AUD, which is our overall goal.  
3¬†
¬† 
 
3.2 Purpose of Study/Potential Impact 
The proposed project will help fulfil the ACGT‚Äôs goal of translat ing preclinical findings into clinical trials leading to new 
pharmacologic approaches to the treatment of alcohol use disorder (AUD). 
 The goal of the proposed Pilot project is to translate basic science findings from Alcohol Center for Genes and Translation 
(ACGT) preclinical investigators into clinical research to improve the treatment of alcohol use disorder (AUD). AUD is 
difficult to treat, and currently available medications are under utilized, due at least in part to their limited effectiveness 
[1-3]. There is a critical need for mo re efficacious medications for AUD.   
 Using preclinical rodent models, ACGT investigator Ron identified the mammalian target of rapamycin complex 1 (mTORC1) [4-8] as a potential drug target for AUD. Lacosami de targets collapsin response mediator protein-2 (CRMP-2) 
[4,12,13], a downstream mediator of mTORC1 [4].  
We will conduct the first controlled pilot human laboratory study to 
assess the effects of two doses of lacosamide, versus placeb o, on alcohol craving, drin king, and psychomotor effects.   
 Based on findings discussed above, the premise of this work is  that (1) molecular mechanisms that drive excessive alcohol 
intake in rodents can also promote heavy drinking in humans wi th AUD, that (2) the use of lacosamide, to inhibit CRMP-2 
[4,12,13], for reducing human drinking is supported by rode nt studies from ACGT researchers and that (3) the Alcohol 
Drinking Paradigm and the proposed measures of neurobehavioral contributors to alcohol drinking are well-validated and are drivers of alcohol use by heavy drinkers with AUD in human  laboratory studies; and that  (4) lacosamide may represent 
a novel pharmacotherapy to treat AUD, which is our overall goal . If successful, our experiment will facilitate the development 
of a new pharmacological strategy for treating human AUD -- i nhibition of CRMP-2.  In addition, it will provide important 
scientific information about the salience of CRMP-2  to human heavy drinking and to human behavioral antecedents to 
drinking.  
3.3 Potential Risks and Benefits 
 
3.3.1 Potential Benefits 
There is no direct benefit to these participants besides referral  to treatment, which will be provided at the end of the study. 
They will be able to withdraw from the study at any time. Th e direct benefit is not great for participants, but given the 
potential benefit to developing effect ive treatments for alcoholism, the ri sk-benefit ratio appears favorable. 
 Participants may benefit somewhat from th e extra physical examination, laboratory tests, and attention. In the informed 
consent form, participants are instructed:  ‚ÄúTaking part in this  study may not make your health better. If you are in this 
study, you may benefit from the physical examinations, blood tests, and review of your symptoms. Others may benefit from 
the overall conclusions drawn from  the results of this study.‚Äù 
 
AUD is major public health problem that contributes prominen tly to the global burden of disease [58].  While there are 
several approved medications for the treatment of AUD, the available pharmacotherapies are hampered by small effect 
sizes, adverse effects, and limited adoption into practice. Currently available FDA-approved  pharmacological agents have 
major limitations and there is a critical need to identify novel medication strategi es for AUD treatment. Despite the large 
numbers of patients who suffer from AUD, medications are grea tly underutilized and only a small minority of adults in the 
United States who have AUD are treated with medications. 
This low utilization is thought to be in part due to a perception 
of AUD medication ineffectiveness . The potential knowledge to be gained in th is study is judged to be highly significant.  
This research seeks to expand the knowledge base regarding the treatment of alco hol use disorder.  Because of the known 
low to moderate risk profile of the study medications and the close monitoring afforded by the study design, the level of 
risk for prospective participants is judged to be modest, and therefore, is considered to be reasonable, in comparison with 
the potential knowledge to be gained. 
 
The results of this laboratory-based drinking paradigm will pro vide an important initial signal regarding the potential efficac y 
of lacosamide in reducing alcohol drinking. There is a grea t need for the development of new agents and combination of 
agents to treat alcohol use disorder. This  laboratory paradigm will also provid e information regarding the mechanism of 
action of these agents and thus significantly contribute to the literature .  
 
 
 
4¬†
¬†3.3.2 Potential Risks and Procedures to Minimize Risks 
 The major potential risks in this study are related to administ ration of alcohol, lacosamide, and blood drawing during the 
physical exam and the alcohol drinking period, and risks to privacy.  
 Alcohol 
A number of medical conditions could potentially be worsened by acute alcohol administration (e.g., liver disease, cardiac abnormality, pancreatitis, diabetes, neurological problems, diab etes, and gastrointestinal disorders). During screening, the 
study physician will conduct a medical history and physical exam  and review laboratory findings.  As a result, participants 
with medical problems that are judged by the study physic ian/PI (Dr. Batki) will be excluded from the study. 
 Alcohol may also cause nausea in high dose s; however, nausea is not expected at the dose being used in this sample of 
heavy drinkers. Participants will not be dr inking to levels more than they typical ly consume in their own drinking context, 
and, with the exception of the priming dose, they determine the amount of alcohol consumed.  
Another area of potential risk to participants under the influence of alcohol involves their safety during the experimental 
procedures. Although impairment of gross motor coordination in  heavy drinkers is rare at the alcohol dose used in this 
study, all participants will be under the supervision of the experimenters to prevent possible accidents such as falls. 
Participants will not leave the laboratory during the self-administration procedure,   Alcohol is a reinforcing agent, which may cause changes in be havior including repetitive or excessive alcohol consumption. 
Because of this, the administration of alcohol to alcoholics in treatment could potentially impede the progress of their 
recovery. In addition, the administration of alcohol to sober alcoholics living in the community presents a possible risk of 
relapse. As a result, we will be recruiting non-abstinent no n-treatment-seeking alcoholics in keeping with the National 
Advisory Council on Alcohol Abuse and Al coholism's recent update of its 1989
41 recommended guidelines on ethyl alcohol 
administration. At completion of the study, we will make a seri ous and concerted effort to link the participant with treatment 
for their alcohol problems. This will be done by giving the part icipant objective feedback about the fact that their drinking 
exceeds standards for avoiding hazardous drinking, providing a br ief one-session motivational intervention for their drinking, 
and by arranging for alcohol treatment services if they are interested. In our previous and ongoing work, several participants quit drinking and many others reduced their drinking in the three months following this intervention. 
 
***Protection against risks of alcohol challenges*** 
The alcohol challenges will be conducted by Dr. Batki and rese arch staff, using methodology adopted from the Yale group, 
and trained by our Yale colleague, Dr. Suchitra Krishnan-Sarin.   We provide a number of safeguards to reduce the risk of physic al injury by supervising all sessions and having participants 
stay in the CRC until they are alert and do not show signs of  psychomotor impairment. We al so exclude participants for 
whom physical or psychological problems contraindicate alcohol consumption. By selecting non-treatment-seeking 
participants who are currently drinking heavily on a regular basis,  we are not exposing participants to alcohol consumption 
levels that differ from their normal drinking context. Although  this has not happened in the Yale group‚Äôs experience, should 
a participant insist on leaving the research setting prematurely, we will provide transportation back to their residence. This contingency will be explicitly addressed in the consent form.   Clearly, participants are free to discontinue the experiment at any time, although we would strongly encourage them to 
remain in the research setting until their blood alcohol level is below .02 and alertness and psychomotor status are judged 
to be safe.  
 Because participants are not in treatment, participation in an alcohol challenge study will not interfere with efforts to achie ve 
abstinence. At the end of the study, however, a potential benefit  is that participants will be provided with a professional 
evaluation and treatment will be arranged if they express interest. 
 
***Protection against the risk of heavier alcohol use, suicidalit y, or other medical or psychiatric problems that may arise 
over the course of the study*** 
To protect against this risk, we will do the following: 
-We will closely monitor alcohol use at each visit. -Participants will be withdrawn from the study if, in the opinio n of the PI or the DSMB, there is: sustained clinically signifi cant 
increase in alcohol use between ADP sessions 1, 2 and 3, suicidal ideation consisting of suicidal  intent or plan, unacceptable 
5¬†
¬†adverse events judged by the study physician (the PI, Dr. Batki) to be related to study interven tions, or any other clinically 
significant medical, psychiatric, or subs tance use related poor outcome that makes continued study participation unsafe. 
 
Blood and Urine Collections 
Screening blood and urine collections are performed primarily as safeguards to participants and should add no risks other 
than those normally associated with these procedures. Partic ipants will have approximately 40 cc of blood drawn at the 
intake appointment to determine liver and kidney functioning, an d during the self-administration portions of the study we 
will draw approximately 20 cc of blood at each of the 3 visits. Therefore, the total amount of blood drawn during the study 
(100 ml) poses minimal risk in healthy part icipants. We will advise participants agai nst donating blood for six weeks following  
study participation. 
 Risk of Study Medication - Lacosamide 
 Adverse effects The 10 most common adverse effects asso ciated with lacosamide 200 mg/day (100 mg twice per day) when used as 
adjunctive therapy  in patients with partial-onset seizures (placebo comparison in parentheses) were: dizziness 16% (8%); 
headache 11% (9%); nausea 7% (4%); fatigue 7% (6%); vomiting 6% (3%); diplopia 6% (2%); vomiting 6% (3%); vertigo 5% (1%); somnolence 5% (5%); tremor 4% (4%); ataxia 4% (2%)
13.  
 Relevant Warnings/ Precautions in FDA-approved Package Insert for Lacosamide (Vimpat¬Æ)
 
Suicidality associated with anticonvulsants   
Even though participants will be exposed to only a single dose of lacosamide, it has been noted  that ‚Äúall antiepileptic drugs 
including lacosamide increase the risk of these thoughts or  behaviors in patients taking these drugs for any indication‚Äù13. 
An FDA Alert, updated 12/16/2008, (US Food and Drug Admi nistration 2008) 11 antiepileptic or anticonvulsant drugs 
associated with:  ‚Äúreports of suicidality (suicidal behavior or ideation [thoughts])‚Ä¶FDA is requiring ‚Ä¶ that all manufacturers 
of drugs in this class include a Warning in their labeling....  FDA‚Äôs pooled analyses of 199 clinical trials of eleven antiepil eptic 
drugs‚Ä¶ showed that patients who received one of the antiepilept ic drugs had almost twice the risk of suicidal behavior or 
ideation (0.43%) compared to patients who received placebo (0.24%). This‚Ä¶ represents the occurrence of approximately 
one additional case of suicidal thinking or behavior for every 530 patients treated with an an tiepileptic drug‚Ä¶ The increased 
risk was observed as early as one week after starting treatment and throughout th e observed duration of treatment. The 
increased risk of suicidal thoughts or behavior was generally consistent among the eleven drugs with varying mechanisms 
of action and across a range of indications. This observation suggests that the risk applies to all antiepileptic drugs used 
for any indication‚Ä¶.‚Äù Dizziness and ataxia  
The package insert notes this as a warning/precaution13. See above for incidence of these adverse effects. At the doses 
that we will be using, dizziness and ataxia could be expected  to occur in 16% and 4% of participants, respectively, and 
may be increased by combining lacosamide with alcohol.  Cardiac rhythm and conduction abnormalities  
The package insert notes this as a warning/precaution13. It is recommended that an ECG be obtained before starting 
lacosamide and that other medications that  could prolong PR interval be avoided. 
Syncope   
Although listed as a warning/precaution13, the package insert notes that there was no increase in syncope compared to 
placebo in epilepsy patients with no significant system illnesses.  
Controlled substance 
Lacosamide is schedule V controlled subs tance, indicating a potential for human abuse that is the lowest among the 5 
schedules of controlled substances. In a human abuse potentia l study, single doses of 200 mg and 800 mg of Lacosamide 
produced euphoria-type subjective responses
13.  At therapeutic doses, the rate of euphoria reported as an adverse effect 
was less than 1%13. No withdrawal syndromes have been reported. 
 
Interactions of Lacosamide and Alcohol 
There are no published reports of lacosa mide-alcohol pharmacokinetic (PK) or pharmacodynamics interactions.  It is 
reasonable to assume that there may be additive effects of the combination of lacosamide 100mg with alcohol.  Possible 
risks may include added sedation and added psychomotor impairment that could persist for several hours after last alcohol self-administration (2:00-3:00 PM).  It is expected that alcohol effects will wear of f in the ensuing 5 hours before discharge 
from the CRC at 8:00 PM.  Tests of alertn ess and gait/body sway will be  administered throughout the testing day to monitor 
these effects. 
6¬†
¬† 
***Protection against risks of medications*** 
Effective screening will exclude participants who would be at greater risk for complications because of medical, neurological o r 
psychiatric illnesses. Individuals currently dependent on other drugs will be screened out. Participants will be carefully 
monitored during each human laboratory  session and will be given only single, observed doses of study medications.  
Participants will be educated of the risks attendant to study participation through the informed consent process.  
 Protection Against Risks of Lacosamide Participants will take lacosamide only in an observed single dose administration by research  staff.  They will then be 
monitored closely from the time of medication admi nistration at 8:30 until leaving the CRC at 8:00 PM. 
 Protection Against Effects of Lacosamide on Other Medications To protect against this risk, we will do the following: -The study physician will review all concomitant medications an d determine whether there are potential drug interactions 
that need to be avoided. 
-In the informed consent form, participants are instructed, ‚ÄúL acosamide may cause a change (increase or decrease) in the 
effect of some other medications.  If you are taking other medications during your participation in this study, immediately 
inform study staff.  The study doctor will review any medica tions that you are talking and make the determination as to 
whether continued study participation is safe for you.‚Äù  
 Blood Drawing (Venipuncture) Risks  
Participation in the study requires participants to have th eir blood drawn 4 different times over the course of study 
(screening and human laboratory ADP sessions 1, 2, and 3).  Having bl ood drawn may cause pain (common), 
fainting/passing out (not very often), a bruise where the needle goes in (not very often), and infection at the same place (rare).  
 
***Protection against blood drawing (venipuncture) risks*** 
To protect against this risk, we will do the following: 
1) Professionally trained phlebotomists at the CTSI C linical laboratory will pe rform all phlebotomies.  
 Risk of Privacy/Confidentiality 
Participation in the study presents a risk to the participant of  loss of privacy and confidentiality regarding research materia l, 
particularly with respect to potentially em barrassing or harmful personal health  information, particularly related to 
mental health and alcohol and substance use. This includes detailed and sensitive information regarding alcohol and drug 
use, and psychiatric symptoms.  For example, urine drug te sting will be conducted.  Potential release of information 
regarding drug use, in particular, could have serious im plications if made known, for example legal ramifications, 
jeopardizing  insurability or employability.    
In order to ensure the safety of the participant and others , information may be shared between research staff and the 
clinical team only under the following circ umstances: 1) If in the judgment of the study physician, the participant has a 
psychiatric or medical condition that requir es urgent attention to protect the safety of the participant or others; and 2) If a  
participant has missed several study appointments, and research  staff needs to verify the participant's whereabouts and/or 
verify the participant's safety.  These above circumstances will be clearly outlined  in the informed consent form, and be 
discussed and clarified with prospective participants at the start of the study.  
***Protection against risks to privacy/confidentiality***  
To protect against this risk, we will do the following: ÔÇ∑ In the informed consent form, participants are instructed: ‚ÄúP articipation in research may involve a loss of privacy, but 
information about you will be handled as con fidentially as possible.  If you do not already have a medical record at the VA 
Medical Center, San Francisco, one will be created because of your participation in this study.‚Äù 
ÔÇ∑ 
HIPAA regulations will be followed throughout this study. Several methods will be used to decrease the risk of loss  of 
confidentiality to participants.   o First, all study forms will be labeled wi th a unique, identifying code number, and maintained in a locked cabinet. Those 
that contain the names of participants or other identifying info rmation will be stored in a locked cabinet, separate from 
other study forms.   
o Second, research material will not be shared between the re search team and clinical staff - with the exception of 
information to be shared only to ensure the safety of the participant and others.   
7¬†
¬†o Third, no names will be used in any published reports about this study.   
o Fourth, most of the questionnaire data  will be collected using an online survey instrument called Qualtrics: 
All collected research data will be refere nced by unique study identification codes on ly, stored in an electronic database 
(SQL server) on a password-protected secure VA server behind a secure VA firewall at SFVAMC available to study staff only. 
After receiving CHR and R&D approval, we will be collecting most  of our questionnaire measures in digital format, so that 
this questionnaire data can be collected using an online surv ey instrument called Qualtrics, which meets strict IRB and 
HIPAA data security requirements. Data will be entered into SQ L Server tables using MS Access as a front-end or batch load 
from an external file.  At a point of entry, form values are subjected to consistency edit checks (e.g. range and type verification, missing data). Scoring algorithms are applied wher e appropriate. Once data is entered into the database, edit 
checks are run for accuracy.  Unknown Risks 
Participants may experience side effects that are not known yet.  
 
***Protection against unknown risks*** 
To protect against this risk, we will do the following: -During the informed consent process, participants will be notified about the possibility of unknown risks associated with taking lacosamide or their combination with alcohol.  -During the informed consent process, the possibility of unknown  risks are explained and that researchers will let participants 
know if new information about risks and side effects becomes available over the course of the study.  
-Adverse effects will be carefully moni tored during each ADP lab session. 
 
4. STUDY OBJECTIVES  4.1 Hypothesis Include a clearly defined hypothesis, if relevant, and list the key questions the study is expected to answer. Be detailed, 
clear and as specific as possible. 
 
4.2 Primary Objective As this is a small pilot study, the Primary Aims are 
process- rather than outcome -oriented:   
 
1. To establish the feasibility and safety of giving lacosa mide to human participants in a laboratory alcohol self-
administration procedure; and   2. To allow our research team to  gain experience with these procedures and fine-tune them.   
 4.3 Secondary Objectives The Secondary Aim is to obtain a preliminary assessment of the effects of  lacosamide on alcohol consumption and related 
behaviors in individuals with AUD.   
5. STUDY DESIGN  5.1 General Design We will conduct a double-blind, placebo-controlled, within-s ubjects pilot laboratory tria l. Four heavy-drinking, non-
treatment seeking community volunteers with AUD will each undergo 3 ADP human laboratory sessions.  They will be 
randomly assigned to receive a single dose of either 1) lacosamide 100 mg, 2) lacosamide 200 mg, or 3) placebo, in a balanced crossover design, in each of 3 human laboratory sessions, with 1 week between sessions. In each session, 2 
hours after medication administration, participants will undergo  a series of tests (impulsivit y, craving, alcohol approach-
avoidance task, and as a control measure, a reaction time task (the 
Digit Vigilance Test ), followed by a priming drink and 
two alcohol self-administration periods, using the ADP. 
 
5.1.1 Study Duration The study begins with a screening visit that is expected to  last approximately 3 hours. If it is deemed safe for the 
participant to enroll in the study and they meet all eligibilit y criteria, then the participant will be scheduled for 3 human 
lab sessions, each 12 hours long. The human lab sessions will take place on separate weeks with at least 7 days, or a 
washout period, before the next human lab session can comme nce. A follow-up visit will be scheduled at least 7 days 
after the 3
rd and final human lab session.   
8¬†
¬† 
5.2 Outcome Variables This section describes the primary and secondary outcome vari ables, which are the endpoints that will be used to assess 
the study.  5.2.1 Primary Outcome Variables The primary outcome variables are measures of feasibility: 
1. Time needed to recruit, screen, and run the study procedures for 4 participants. 
2. Retention rates at the various in the study process (s creening, Human Lab ADP session 1,2,3, and follow-up). 
3. Adverse effects of study medication  (lacosamide at 2 doses and placebo), before and after alcohol self-
administration.  
5.2.2 Secondary Outcome Variables Secondary outcomes: 
1. Alcohol craving 
2. Alcohol consumption during each of the 3 Human Lab ADP sessions. 
3. Alcohol ‚Äì medication interaction effects on BAES, DVT,  MD gait and body sway check, Alertness VAS and 
computer tasks (AAT, BART, and DD)  
5.3 Study Population A total of 4 male non-treatment seeking healthy community volunteers will be enrolled. 
 
5.3.1 Number of Participants The study will enroll 4 men participants. We anticipate needing to start up to 6 participants to get 4 to complete all 3 
human lab sessions.  5.3.2 Eligibility Criteria 
 
Inclusion Criteria: 
1. Men, ages 21-50; 2. Able to read English and to complete study evaluations; 3. Meet DSM-V criteria for current alcohol use disorder (AUD); 
4. Average weekly alcohol use of 25-70 standard drinks for men over the past 30 days; 
5. No more than an average of 3 days/week of alcohol ab stinence in the past 30 days, to maximize likelihood that 
participants will choose to drink during the laboratory sessions. 
 Exclusion Criteria: 
1. Individuals who are seeking AUD treatment or ha ve been in treatment within the past 6 months; 
2. Current DSM-V non-alcohol substance use disorders other than tobacco and cannabis; 
3. Positive urine drug test results at more than one scre ening appointment for opioids, cocaine, benzodiazepines, or 
barbiturates; 
4. Regular use of psychoactive drugs including antipsycho tics, anxiolytics and antidepr essants during the 30 days 
prior to entry, as well as regular us e of anticonvulsants, beta blockers, central nervous system stimulants or 
depressants, or other drugs that cause excessive sedation; 
5. Taking medications that may interact with lacosamide, e.g. medications that prolong the ECG PR interval, or 
medications with strong CYP3A4 and CYP2C9 inhibition; 
6.  Psychosis or any other serious mental illness as judged by SCID and st udy physician assessment; 
7. Medical conditions that in the judgment of the stud y physician contraindicate the consumption of alcohol; 
8. Medical conditions that in the judgment of the study ph ysician contraindicate LAC (no contraindications listed in 
the FDA-approved Prescribing Information for LAC); 
9. Any other medical conditions that in the opinion of th e study physician would make study participation hazardous; 
10. History of serious alcohol withdrawal  (e.g. seizures, DTs, hospitalization) or a Clinical Institute Withdrawal 
Assessment Scale (CIWA-AD) score > 8; 
11. Participants who report disliking spirits will be exclud ed because 80 proof liquor will be provided during the 
alcohol self-administration periods; 
12. Participants who have taken any investigatio nal drug within 4 weeks preceding study entry. 
9¬†
¬†13. Participants with first-degree atrioventricular block (A V block), PR interval lengthened beyond 0.20 seconds, or 
greater. 
 
6. METHODS 
 The study will consist of the following steps, replicating the Yale ADP methods:  (1) Recruitment;  
(2) Pre-screening: Brief telephone or in-person to determine eligibility for full screening beginning with establishing non-
treatment seeking status;  
(3) Full Screening/baseline visit: 1-2 in-perso n visits to obtain consent and to evalua te eligibility (e.g. to reject participa nts 
with medical conditions): a diagnosis of AUD  and heavy drinking criteria , and by confirming that the individual is non-
treatment seeking . If these criteria are met, physical examination and laboratory testing will be conducted. Eligible 
participants then proceed to  
(4) Human Lab ADP Sessions 1, 2, and 3, in which partic ipants will receive a single dose of lacosamide 100 mg, 
lacosamide 200 mg, or placebo. The order of medication s will be randomly assigned and counterbalanced across 
participants. Between each session, there is a 7-day wa shout period when no study medication is given.  
(5) The day following each ADP Session, a study staff member will call the participant to ask about well-being, assess for 
adverse effects and collect drinking data. (6) Participants then undergo a 1-week Follow-up visit, wh ere adverse events and alcohol use will be assessed and a 
research clinician will provide a motivational enhancement se ssion to encourage these non-tr eatment seeking participants 
to consider treatment and provided with referral materials.  
 
 
6.1 Treatment ‚Äì Drug 
 6.1.1 Identity of Investigational Product 
Lacosamide (LAC) is a functionalized amino acid analogue of D-serine, and is FDA-approved as an anticonvulsant for the 
treatment of partial-onset seizures. The pharmacokinetic profile  of LAC indicates it is rapidly and completely absorbed 
after oral administration with neglig ible first-pass effect and a high absolute bioavailability of approximately 100%, 
minimal CYP450 interaction, low (<15%) protein binding. Food  does not affect rate and extent of absorption. The 
maximum LAC plasma concentrations occur approximately 1-4 ho urs post dose after oral do sing and elimination half-life 
is approximately 13 hours [91]. There is no publis hed data in humans on LAC-alcohol interactions. 
 
6.1.2 Dosage, Admin, Schedule The manufacturer for lacosamide (LAC) (Vimpat¬Æ) has no in volvement with the study.  The Wellspring Compounding 
Pharmacy (WCP) in Oakland, CA is selected by the SFVA MC Research Pharmacy to compound placebo-controlled 
medications. WCP will obtain LAC from the manufacturer, and prepare 100 mg of LAC, 200mg capsules of LAC, and 
matching placebo.  The SFVAMC Research Pharmacist will directly receive all study medications from WCP and store 
10¬†
¬†appropriately. A single dose of either LAC 100 mg, LAC 200 mg or matching placebo will be given in each of the 3 Human 
Lab Sessions. 
 
6.1.3 Method of Assignment/Randomization 
Participants will be randomly assigned to one of 3 sequence s for the 3 Human Lab ADP sessions, in a balanced within-
subjects crossover design.  6.1.4 Blinding and Procedures for Unblinding Matching study medications will be prepared by Wellspring Pharmacy and stored and dispensed by the SFVAMC Research 
Pharmacist.  The Research Pharmacist will keep the randomization list.  The investigators and participants will be blinded to the particular sequence of medication assignments.  6.1.5 Packaging/Labelling The SFVAMC Research Pharmacist will manage these proc edures: The Wellspring Compounding Pharmacy (WCP) in 
Oakland, CA is selected by the SFVAMC Research Pharmacy to compound placebo-controlled medications. WCP will obtain 
LAC from the manufacturer, and prepare 100 mg of LAC, 200mg capsules of LAC, and matching placebo.  The SFVAMC 
Research Pharmacist will directly receive all study medications from WCP and store appropriately. A single dose of either 
LAC 100 mg, LAC 200 mg or matching placebo will be given in each of the 3 Human Lab Sessions.  6.1.6 Concomitant Therapy  
Participants will be informed that they cannot use psyc hoactive drugs including antipsychotics, anxiolytics and 
antidepressants during the 30 days prior to entry, as well as anticonvulsants, beta blockers, central nervous system 
stimulants or depressants, or other drugs that cause exce ssive sedation in the judgment of the study physician/PI. 
 6.1.7 Restrictions  
As per Exclusion Criteria, above.  
6.2 Assessments  
Please see the list of study measures below, Sec. 6.3.5 
 6.2.1 Efficacy This is a pilot feasibility study, not an efficacy study. The primary outcome variables are measures of feasibility: 
1. Time needed to recruit, screen, and run the study procedures for 4 participants. 
2. Retention rates at the various in the study process (s creening, Human Lab ADP session 1,2,3, and follow-up). 
3. Adverse effects of study medication  (lacosamide at 2 doses and placebo), before and after alcohol self-
administration. 
 
6.2.2 Safety  
Please see the study procedures, below, Sec. 6.3.5, and steps to minimize risks, above, in Sec.3.3.5. 
 6.2.2.1 Adverse Events Definition and Reporting  Adverse Events During the study, site personnel will note any change in th e condition(s) and the occurrence and nature of any adverse 
events. For 7 days after the last dose of study supplement/pla cebo (post-discontinuation evaluation) participants will be 
closely followed for study drug-related adverse events in orde r to detect delayed toxicity. If drug-related toxicity is 
present beyond 7 days post last dose, participants will be followed every 7 da ys until the toxicity resolves, another 
therapy is initiated, or death. Import ant clinical information that comes to light during study participation will be 
communicated by research coordinators to the study physician in real time. 
  
The study physician (either the PI, Dr. Batki, or, in his ab sence, the study sub-I, Dr. Ellen Herbst) will review each 
participant‚Äôs safety at each study visit. 
-Lab results will be reviewed on the sa me day that the results are received. 
-Adverse effects reported by participants will be reviewed on the same day as they are reported by the study participant. -Adverse effect assessment will be done  by the research coordinators and discussed with the study physician on a daily 
basis, immediately after these adverse effects are repo rted by the participant to the study coordinator. 
  
11¬†
¬†As with our current, CHR-approved clinical trials, the study physician, if not immediately present at the time of adverse 
effect data collection, will be contacted in real time by the study coordinator by phone, pager, or text message, so that 
adverse effects can be discussed with the study physician. Th e study physician, based on examination of the participant 
and/or review of the participant‚Äôs data, will make a clinical ju dgment at each visit regarding wh ether it is safe to proceed 
with study medications. 
  The PI will report to the IRB, DSMB and study sponsor his assessment of the potent ial relatedness of each AE to protocol 
procedure, studied disease state, study dr ug via the CRF. For each adverse event recorded on the Adverse Event CRF, the 
PI will make an assessment of seriousness, severity, and causality. 
  
According to the ICH guideline for Good Clinical Practice , an adverse event is any untoward medical occurrence in a 
clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An adverse event 
can therefore be any of the following: 
ÔÇ∑ Any unfavorable and unintended sign (including an abnorm al laboratory finding), symp tom, or disease temporally 
associated with the use of a medicinal product, whethe r or not considered related to the medicinal product. 
ÔÇ∑ Any new disease or exacerbation of an existing disease (a worsening in the character, frequency, or severity of a 
known condition). 
ÔÇ∑ Recurrence of an intermittent medical conditio n (e.g., headache) not present at baseline. 
ÔÇ∑ Any deterioration in a laboratory value or other clinical test  (e.g., ECG, X-ray) that is associated with symptoms or 
leads to a change in study treatment or concomitant treatment or discontinuation from study drug. If a 
participant‚Äôs dosage is reduced or trea tment is discontinued as a result of an AE, the PI will report to the study 
sponsor via CRF the circumstances and data leading to  any such dosage reduction or discontinuation of 
treatment. 
  Events leading to the clinical outcome of death from progre ssive disease will not be recorded as adverse events unless 
the PI believes that the event may have been caused by the study drug.   Serious adverse event (SAE) collection begins after the part icipant has signed informed consent and has received study 
drug. If a participant experiences an SAE after signing inform ed consent, but prior to receiving study drug, the event will 
NOT be collected unless the PI feels the event ma y have been caused by a protocol procedure. 
  
The PI will alert the study sponsor of any SAE within 24 hour s of the PI‚Äôs awareness of the event. Alerts issued via 
telephone will be immediately followed with offic ial notification on study-specific SAE forms. 
  
An SAE is any adverse event from this study th at results in one of the following outcomes: 
ÔÇ∑ death (excluding death due to progression of study disease, unless related to study drug); 
ÔÇ∑ initial or prolonged inpatient hospitalization; 
ÔÇ∑ a life-threatening experience (that is, immediate risk of dying); 
ÔÇ∑ persistent or significant disability/incapacity; 
ÔÇ∑ congenital anomaly/birth defect; 
ÔÇ∑ considered significant by the PI for any other reason. 
  Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered 
serious adverse drug events when, based upon appropriate medical judgment, they may jeopardize the participant and 
may require medical or surgical intervention to prevent one of the outcomes listed in this definition.   Serious adverse events (SAEs) occurring after a participant ha s taken the last dose of study drug will be collected for 7 
days after the last dose of study drug, regardless of the PI‚Äôs  opinion of causation. Thereafter, SAEs will not be reported 
unless the PI feels the events were related to either study drug, or drug delivery system, or a protocol procedure. Any 
SAE occurring prior to enrollment that the PI believes may have  been caused by a protocol procedure will be reported to 
the study sponsor within 24 hours of the PI‚Äôs aw areness of the event and recorded on the CRF. 
  
Study-specific clinical outcomes of death from progressive disease will be reported as SA Es 
 only if the PI deems them 
related to use of the study drug. 
  
 
 
12¬†
¬†Immediate Reporting Requirements From 
 PI to Sponsor: 
Certain events will be immediately reported to allow the Spon sor to take appropriate measur es to address potential new 
risks in a clinical trial. The PI will report such events to the Sponsor immediately; under no circumstances will be reporting 
take place more than 24 hours after the PI learns of the event.  The following is a list of even ts that the PI will report to 
the Sponsor within 24 hours after learning of the event, regardless of relationship to study drug: 
Serious adverse events 
Non-serious adverse events of special interest 
Pregnancies 
  The PI will report new significant follow-up information for thes e events to the Sponsor immediately (i.e., no more than 
24 hours after becoming aware of the information). New significant information includes the following: 
ÔÇ∑ New signs or symptoms or a change in the diagnosis; 
ÔÇ∑ Significant new diagnostic test results; 
ÔÇ∑ Change in causality based on new information; 
ÔÇ∑ Change in the event‚Äôs outcome, including recovery; 
ÔÇ∑ Additional narrative information on the clinical course of the event. 
  Emergency Medical Contracts  
 
Medical Monitor Contact Information: Any life-threatening (i.e., imminent risk of death) or fatal AE th at is attributed by the PI to the investigational product wil l 
be telephoned to the Medical Monitor i mmediately, followed by submission of written case details on an CRF within 24 
hours.   
The following is the contact information that will be utilized by the PI: 
MEDICAL MONITOR Anne Richards, MD, MPH SFVAMC/UCSF 4150 Clement Street San Francisco, CA 94121 
Telephone:415/221-4810 x 23312 
Email: anne.richards@va.gov   Follow-up of Participants after Adverse Events  PI Follow-Up: 
The PI will follow all unresolved treatment-related adverse event until the event has resolved to baseline grade or better, 
the event is assessed as stable by the PI, new therapy is initia ted, the participant is lost to follow-up, or the participant 
withdraws consent.    Every effort will be made to follow all serious adverse events  considered to be related to  study drug or trial-related 
procedures until a final outcome can be reported. During the study period, resolution of ad verse events (with dates) will 
be documented on the Adverse Event CRF and in the particip ant‚Äôs medical record to facilitate source data verification 
(SDV). If, after follow- up, return to baseline status or stabilization cannot be established, an explanation should be 
recorded on the Adverse Event CRF.   Data Review - For Phase II or III Sponsor Studies PIs will conduct continuous review of data regarding participan t safety at weekly study group meetings where the results 
of each participant‚Äôs treatment are discussed, as is currently done for the PI‚Äôs other UCSF CHR approved clinical trials. 
The discussion will include the number of participants, si gnificant toxicities as described in the protocol, doses 
adjustments, and observed responses.  6.3 Study Procedures 
Identify all procedures considered experimental, those performe d exclusively for research purposes and those that would 
occur regardless of the research (i.e. standard of care). Incl ude all observations that will take place during the study, and 
13¬†
¬†Study Schedule listing study procedures (visit by visit) with timing intervals to provide a summary for study team and 
reviewers.] 
 
 
 6.3.1 Study Schedule 
STUDY VISIT  WEEK TYPE OF VISIT AMOUNT OF TIME 
1 1 Baseline/screening 3 hours 
2 2 Human lab session 1 12 hours 
Phone visit 1 10 minutes 
 3 WASHOUT  
3 4 Human lab session 2 12 hours 
Phone visit 2 10 minutes 
 5 WASHOUT  
4 6 Human lab session 3 12 hours 
Phone visit 3 10 minutes 
5 7 Follow-up visit 1 hour 
TOTAL 5 visits 40 hours and 30 minutes 
 
6.3.2 Informed Consent 
The process of informed consent will minimize undue influence  or coercion and offer sufficient time for review. Typically 
study coordinators will receive thorough training on the corre ct way to conduct informed consent. On a rare occasion, a 
study physician or project manager will conduct informed consen t. All staff conducting informed consents have at least a 
Bachelor of Arts or Science in a health-related field and/or have 2 years of research-related experience.  Training for the 
administration of informed consent teaches study staff ho w to move through the consent, assessing participant‚Äôs 
comprehension along the way. A staff member in training will (1) shadow a trained staff member conducting informed consent 2 times, then (2) practices info rmed consent with other lab members, an d finally (3) conducts informed consent 
with a participant while another trained lab member watches.  Once the staff member-in-training satisfactorily conducts 
informed consent under the supervision of another trained staff member, the staff-in-tra ining becomes authorized to 
conduct informed consent.  
6.3.3 Screening 
After consent, participants will be sche duled for screening assessments. The screen ing phase is accomplished over a total 
of 1 to 2 visits.  6.3.4 Enrollment 
[Identify who will enroll the subjects in the study and how this process will take place (for in stance, after they have been 
consented, screened and meet eligibility criteria).] 
 6.3.5 On study visits 
Baseline/screening visit 
3 hours Patient Locator form 
Demographics 
Eligibility form 
Electrocardiogram (ECG) 
Medical History 
Physical Exam 
Lab tests 
Height/weight 
Concomitant Medications 
Concomitant Treatment Log 
Columbian Suicide Severity Rating Scale 
AE Checklist 
Breath alcohol test 
Structured Clinical Interview for DSM-5 (SCID) 
Timeline Followback (TLFB) 
Clinical Institute Withdr awal Assessment (CIWA-AD) 
14¬†
¬†Urine Drug Screen (UDS) 
Family Tree Questionnaire (FTQ) 
Barratt Impulsiveness Scale (BIS-11) 
Alcohol Use Disorders Identification Test (AUDIT) 
Vitals 
Balloon Analogue Risk Task (BART) 
Delay Discounting (DD) 
Human Lab Sessions 1, 2 and 3 
12 hours each human lab Weight 
AE Checklist 
Concomitant Medications 
Approach Avoidance Task (AAT) 
Breath alcohol test 
Timeline Followback (TLFB) 
Clinical Institute Withdr awal Assessment (CIWA-AD) 
Urine Drug Screen (UDS) 
Blood alcohol level 
Vitals 
Alcohol Urge Questionnaire (AUQ) 
MD gait and body sway check 
Concomitant Treatment  
Digit Vigilance Test (DVT) 
Biphasic Alcohol Effects Scale (BAES) 
Yale Craving Scale ‚Äì Short (YCS) 
Balloon Analogue Risk Task (BART) 
Delay Discounting (DD) 
Ratings of Drinking Behavior During the Alcohol Self-Administration Period 
Phone visits 1, 2, and 3 
10 minutes each phone call AE Checklist 
Timeline Followback (TLFB) 
Follow-up Visit  
1 hour Participant End of Study Questionnaire 
AE Checklist 
Breath alcohol test 
Timeline Followback (TLFB) 
Alcohol Urge Questionnaire (AUQ) 
Medical Management (MM) 
 
Assessments at Study Entry and During and After Human Lab Sessions  At Entry:  
These are adapted from previous/ current clinical st udies at the UCSF/SFVAMC Addiction Research Program.  
‚ñ™ Demographic data, will be assessed with data on age, race, socioeconomic status, mari tal status, educational and 
occupational levels, and significant medical history.   
‚ñ∫A number of safety evaluations are included: Medical hist ory and physical examination; Suicide Risk Assessment:   The 
Columbia Suicide Severity Rating Scale [101]. It is a standa rd, thorough, frequently used method to screen for suicidal 
ideation, used by our group in alcohol use disorder clinical trials;   ÔÇß Clinical Laboratory Tests for Health/Safety Monitoring: Blood samples will be  collected for chemistry, liver panel, renal 
panel and complete blood count (CBC); urine will be collected for urinalysis and urine pregnancy tests on women of childbearing potential;  
ÔÇß ECG: an electrocardiogram will be performed to check cardiac cond uction, in particular for PR interval prolongations, as 
this is of relevance to LAC, which can cause small, dose-related increases in mean PR interval 
‚ñ™ Structured Clinical Interview for DSM-5, (SCID)  [96]: the SCID will be used to determine DSM-V diagnosis of current 
(current year) Alcohol Use Disorder, and the DSM-V current psychiatric diagnoses for anxiety, mood, psychotic, and non-
alcohol substance use disorders in order to determine study eligibility.  
‚ñ™ Alcohol Use Disorders Identification Test (AUDIT):  The AUDIT [97] is valid and reliabl e self-report measure of alcohol-
related problem severity.  ‚ñ™ Barratt Impulsiveness Scale (version 11) (BIS-11)  [98]: This provides a trait measure of impulsiveness and will be used 
to characterize the study cohort at study entry.  
15¬†
¬†‚ñ™ Study Physician Review: All health measures, medical history/exams and labs will be reviewed by a study physician to ensure 
that the subject meets all the eligibility criteria and are ready for randomization 
 
At Entry and at various times throughout the study:   
‚ñ™ Clinical Institute Withdrawal Assessment for Alcohol, DSM- IV Version (CIWA-AD): at entr y and before each Human Lab 
Session and at each Follow-up; 
‚ñ™ Urine Drug Screen:  For opioids, benzodiazepines, cocaine, amphetamines, barbiturates:  at entry and before each Human 
Lab Session; ‚ñ™ Breath alcohol concentration (BrAlc);  at entry and before each Human Lab Session; and du ring each Human lab Session  
‚ñ™ Vital Signs : Temperature, heart rate, and blood pressure will be meas ured at study entry and multiple times during each 
Human Lab Session.  
‚ñ™ Concomitant Medications Review:   at entry and before each Human Lab session: thorough review of all concomitant 
medications (prescription or over-the-counter) in the pa st 30 days, as well as those started during the study. 
‚ñ™ AE Checklist: At Entry and at Human Lab Session 1, 2 and 3; Phone visits 1, 2, 3; 1-wk FU; The most commonly experienced 
side effects listed in the FDA package insert will be revie wed. Participants will be asked how many times they have 
experienced each side effect since the last study visit and severity. ‚ñ™ Timeline Followback (TLFB):   at study entry, then Human Lab Session 1, 2 and 3; phone visits 1, 2 and 3. TLFB will be 
used to calculate standard drinks consumed per week in the past 30 days prior to consent and at the two Human Lab 
Sessions, and the 1-week follow-up. The TLFB will be used  to determine whether subjects meet minimum alcohol 
consumption criteria at entry. Other substa nce use will also be collected by TLFB.  
‚ñ™ Balloon Analogue Risk Task (BART): at each Human Lab session after medication 
‚ñ™ Delay Discounting: at each Human Lab session after medication 
 At Follow-up visit: ‚ñ™ Medical Management: at the follow-up visit, research clin ician will provide a motivational enhancement session to 
encourage the non-treatment seeking participants to consider treatment.   
Measures of Alcohol Effects:   
‚ñ™ Breath alcohol concentration (BrAlc) [99] 
at each visi t, and multiple times in ADP Sessions 1 and 2 . BrAlc will be measured 
at each session to detect recent alcohol use with the Intoximeters Alco-Sensor IV  instrument.  
‚ñ™ Blood Alcohol Levels : Human Lab Sessions 1 and 2 (Table 1) : Blood samples will be drawn to measure plasma levels of 
blood alcohol (BAC) during the priming dose and during the alcohol self-administration paradigm.   Blood samples will be stored at -4¬∞C and will be analyzed at the San Francisco VA.  
‚ñ™ Biphasic Alcohol Effects Scale (BAES) [81]: Human Lab Sessions 1 and 2 (Table 1).  This 14-item self-report rating scale 
measures alcohol stimulant/ sedative effects and is used regularly in the Yale ADP.   
‚ñ™ Alcohol Urge Questionnaire (AUQ):  At study entry; multiple times in Human La b Sessions 1 and 2 (Table 1); 1-wk FU; 1-
mo FU:  The AUQ is an 8-item questionnaire assessing desire, expectation of positive effect, and inability to avoid drinking 
if alcohol is available. The AUQ is a reliable and valid scale for the measur ement of self-reported alcohol urges. Its brevity 
and time frame for ratings (i.e. right now) makes it suitable for the ADP.  
ÔÇß Yale Craving Scale -Short (YCS): Multiple times in Human La b Sessions 1 and 2; visual analog scale that measures craving 
for alcohol 
‚ñ™ Ratings of Drinking Behavior During the Alcohol Self-Administra tion Period: multiple times in in Human Lab Sessions 1 and 
2. Subjects will be videotaped during the alcohol self-administration portion of ADP 1 and ADP 2. Videotapes will be rated by two independent for the onset and offset  of each sip of alcohol. Dependent meas ures will be constructed including time 
until the first sip and average time to consume each drink. ‚ñ™ Vital Signs: Human Lab Sessions 1 and 2 (Table 1).   These will include heart rate, blood pressure, and skin. The blood 
pressure cuff will be on subject's dominant arm while the probe of will be attached to the middle finger of the subject's non-dominant arm.   These data will be further used to examine the safety of using the study medications during alcohol self-administration.   
Participant Incentives 
 
STUDY VISIT REIMBURSEMENT AMOUNT 
Screening/baseline $85* 
ADP Lab Session 1 $224** 
ADP Lab Session 2 $224** 
ADP Lab Session 3 $224** 
16¬†
¬†Follow-up visit $25 
Bonus for completing ADP Sessions 1 + 2 + 3 $50 
Total $832 
 
*At the screening/baseline visit, participants are paid per task they complete. At the end of screening, they will earn $85. 
 **Participants will receive $200 for each ADP Lab Session they complete. They could earn an additional $24 per ADP Lab 
Session, depending on ho w many drinks they consume per session. At each session, participants are offered 8 drinks, 
each worth $3. They will receive $3 per drink for every drink that is not consumed.   6.3.6 Removal of participants 
 
Stopping Rules  
Discontinuation of participants: 
Participants for whom there has been at least 2 weeks with out participant contact will be discontinued from the study. 
Exceptions may be made after discussions with the PIs, approval by the Medical Monitor, and consistency with the regulations of the Institutional Re view Board/Ethics Committee (IRB/EC). 
  
Discontinuation of study: 
The study will be stopped if, in the judgment of the DSMB or the PI, there are sufficient safety concerns that arise during 
the conduct of the study that would indicate that participants  are being harmed by the study interventions. Examples of 
such safety concerns would be: -Other events that pose unacceptable ri sks to participants, e.g., multiple SAEs that are judged to be related to study 
interventions.   Withdrawal Rules 
 
Discontinuation of Participants: 
If a participant who does not meet enrollment criteria is enrolled, the study sponsor will be contacted. In such cases, the PI will provide information on the participant¬¥s anticipated be nefit or current benefit from being enrolled in the study or 
continuing to receive study drug respectively. In addition, the PI will discontinue participants from the study drug or the study or both in the following circumstances: 
 
ÔÇ∑ Participant has evidence of progressive disease. 
ÔÇ∑ The participant, for any reason, requires treatment with  another therapeutic agent that has been demonstrated 
to be effective for treatment of the study indication. In this case, discontinuation from the study occurs prior to 
introduction of the new agent. 
ÔÇ∑ The PI decides that the participant should be withdraw n from the study. If a SAE or a clinically significant 
laboratory value is the basis for this decision, the PI  will discontinue the study therapy and take appropriate 
measures. The PI will immediately notify  the study sponsor or its designee. 
ÔÇ∑ The participant or attending physician requests wi thdrawal of the participant from the study.  
ÔÇ∑ The investigator or the study sponsor stops the study or  stops the participant‚Äôs participation in the study for 
medical, safety, regulatory, or other reasons consistent with applicable la ws, regulations, and good clinical 
practice (GCP).  
ÔÇ∑ The study therapies have shown unacceptable toxicity. 
ÔÇ∑ The participant is noncompliant with study procedures. 
ÔÇ∑ In the clinical judgment of the investigator, the partic ipant requires acute detoxification from the alcohol. 
ÔÇ∑ In the clinical judgment of the investigator, the participant's clinical condition worsens substantially (for example, if weekly alcohol use increases 25% or more over baseline) and it is felt to be in the pa rticipant's best interest to 
obtain alternative treatment including, but not limit ed to, additionally psychotherapy, pharmacotherapy, 
hospitalization, etc.   
When a participant withdraws before completing the study, th e reason for withdrawal will be documented in the CRF and 
in the source document.  
17¬†
¬†6.4 Statistical Method 
Descriptive statistics will be used to summarize the data set. Measures of central tendency and measures of variability will 
be reported for the chief variables of interest as noted below in 6.4.3.   
 
6.4.1 Statistical Design As this is a pilot feasibility study, no  inferential statistics will be used.  
 6.4.2 Sample Size Considerations Not applicable. 
 
 6.4.3 Planned Analyses Descriptive statistics will be used to desc ribe the data set. Measures of central tendency and measures of variability will 
be reported.  Chief variables of interest are listed below in 6.4.3.1, 6.4.3.2, and 6.4.3.3. 
 
6.4.3.1 Primary Analyses 
Primary analyses will consist of descriptive stat istics. These measures of feasibility are:  
1. Time needed to recruit, screen, and run the study procedures for 4 participants 
2. Retention rates at the various timepoints in the stud y process (screening, Human Lab ADP session 1,2,3, and 
follow-up). 
3. Adverse effects of study medication  (lacosamide at 2 doses and placebo), before and after alcohol self-
administration. 
 6.4.3.2 Secondary Objectives Analyses Descriptive statistics will be used to summarize th e data set. The variables analyzed will include: 
1. Alcohol craving 
2. Alcohol consumption during each of the 3 Human Lab ADP sessions. 
3. Alcohol ‚Äì medication interaction effects on BAES, DVT,  MD gait and body sway check, Alertness VAS and 
computer tasks (AAT, BART, and DD) 
 6.4.3.3 Safety Descriptive statistics will be used to summarize the data. The AE checklist will be used to assess adverse effects.  
Descriptive statistics will be used.  
7. TRIAL ADMINISTRATION  7.1 Institutional Review Board (IRB) Review [Include a statement about IRB oversight and review throughout  the study. This may be institution or sponsor specific.] 
 7.2 Unanticipated Problems [Explain how unanticipated problems that may occur during the study will be handled, communi cated to the IRB, sponsor, 
and FDA, if applicable.]  7.3 Study Monitoring 
[Specify who will monitor the study (third party, sponsor, inte rnal team, etc.), where monitoring will occur and frequency. 
Describe any related responsibilities and identify anyone who will review the study for accuracy and how often.] 
Study monitoring will be conducted by the DSMB.  7.4 Data Safety Monitoring Plan  
Plan to monitor study progress and safety: Th e Data and Safety Monitoring Plan (DSMB)  
The DSMP for this project consists of: 
- a Data and Safety Monitoring Board (DSMB) - a schedule of DSMB meetings to review study data and events - a list of study data and event items to be reviewed by the DSMB - procedures for communicating DSMB findings to the CHR,  the study sponsor (Department of Defense) and other 
appropriate entities 
18¬†
¬†- a plan for conducting and reporting interim analysis 
- stopping rules - rules for withdrawing study participants from the study interventions 
 
These elements of the DSMP are described below:  The Data and Safety Mo nitoring Board (DSMB)  
The Data and Safety Monitoring Board (DSMB) is a group of  3 physicians who are not study investigators and who are 
experts in the area of clinical research and substance use diso rders.  The current composition of the PI‚Äôs DSMB is:  William 
Wolfe, M.D., a clinical investig ator and Medical Director, PTSD Clinic, SFVAMC ; Anne Richards, M.D. [medical Monitor], an 
experienced human clinical investigator, Assistant Professor of Psyc hiatry at University of California, San Francisco and 
Steven Lieske, M.D., Ph.D., an experienced basic neuros cience investigator and attending psychiat rist, SFVAMC. 
 The DSMB will meet biannually to review data reports prepared  by the PI regarding the progress of the study and will 
monitor patient enrollment, retention, outcomes, adverse events, and other issues related to patient safety.  The DSMB will 
make recommendations to the PI as to whether the study shou ld continue or be modified or terminated.  The DSMB can 
consider patient safety or other circumstances as grounds for early termination.   Any member of the DSMB can ask for a 
meeting of the group if he/she feels that it is necessary, based upon the data. 
 During the course of the study, reports will be prepared an d distributed to the Data and Safety Monitoring Board on a 
biannual basis. In order for the Data and Safety Monitoring Board to discharge their duties for overseeing the study and 
the rights of the patients, they will receive analyses of  the primary outcome measures and the important secondary 
measures on a quarterly basis. The DSMB will receive reports of serious adverse events (SAEs) within 72 hours of their 
occurrence.  DSMB Minutes will be prepared by the Study Coordinator wi thin 5 working days after each biannual DSMB meeting. 
 
Medical Monitor  
Anne Richards, M.D., Medical Director of the PTSD Clinic at  San Francisco VA Medical Center will serve as the Medical 
Monitor. As Medical Monitor, Dr. Richards will review all unanticip ated problems involving risk to subjects or others, serious 
adverse events and all subject deaths associated with the protoc ol and provide an unbiased written report of the event.  At 
a minimum, the medical monitor will comment on the outcomes of the event of problem and in case of a serious adverse 
event or death, comment on the relationship to participation in the study. The Medical Monitor will also indicate whether 
she concurs with the details of the report provided by the prin cipal investigator.  Reports for events determined by either 
the investigator or medical monitor to be possibly or definite ly related to participation and reports of events resulting in 
death will be promptly forwarded to the IRB and other governing authorities.  7.5 Study Discontinuation 
[explain the circumstances under which the study may be discontinued] 
If a serious adverse effect occurs and is considered by the PI and DSMB to be study-related, the study will be stopped 
until study procedures can be reassessed and mod ified as needed, with concurrence by the DSMB. 
 7.6 Study Completion We will conduct the following procedures to close-out the study: 
Submit a close-out report to the UCSF CHR 
Submit a notification to the Biosafety Committee to cl ose-out the Biological Use Authorization (BUA).  
Submit notification to the SF VA R&D Commi ttee to close-out the project, BATS-XXXX 
Once all close-out reports have been processed, we will subm it a notification to the study sponsor (ACGT) with all other 
close-out reports.   
7.7 Funding Source 
The study is funded by the University of Californ ia Alcohol Center for Genes and Translation.  
    
 
19¬†
¬†8. REFERENCES 
 1. Koob, G.F. and B.J. Mason, 
Existing and Future Drugs for the Treatment of the Dark Side of Addiction.  Annu Rev 
Pharmacol Toxicol, 2016. 56: p. 299-322. 
2. Spanagel, R., Alcoholism: a systems approach from mole cular physiology to addictive behavior.  Physiol Rev, 
2009. 89(2): p. 649-705. 
3. WHO, W.H.O., Global status report on alcohol and health . 2014: World Health Organization. 
4. Liu, F., S. Laguesse, R. Legastelois, N. Morisot, S. Ben Hamida, and D. Ron, mTORC1-dependent translation of 
collapsin response mediator protein-2 drives neuroada ptations underlying excessive alcohol-drinking behaviors.  
Mol Psychiatry, 2016. 
5. Beckley, J.T., S. Laguesse , K. Phamluong, N. Morisot,  S.A. Wegner, and D. Ron, The First Alcohol Drink Triggers 
mTORC1-Dependent Synaptic Plasticity in Nucl eus Accumbens Dopamine D1 Receptor Neurons.  J Neurosci, 2016. 
36(3): p. 701-13. 
6. Laguesse, S., N. Morisot, K. Phamluong, and D. Ron, Region Specific Activation Of The AKT And mTORC1 
Pathway In Response To Excess ive Alcohol Intake In Rodents.  Addict Biol, 2016. 
7. Neasta, J., S. Barak, S.B. Hamida, and D. Ron, mTOR complex 1: a key player in neuroadaptations induced by 
drugs of abuse.  J Neurochem, 2014. 130(2): p. 172-84. 
8. Neasta, J., S. Ben Hamida, Q. Yowell, S. Carnicella, and D. Ron, Role for mammalian target  of rapamycin complex 
1 signaling in neuroadaptations underlying alcohol-related disorders.  Proc Natl Acad Sci U S A, 2010. 107(46): p. 
20093-8. 
12. Ip, J.P., A.K. Fu, and N.Y. Ip, CRMP2: functional roles in neural de velopment and therapeutic potential in 
neurological diseases.  Neuroscientist, 2014. 20(6): p. 589-98. 
13. Wilson, S.M. and R. Khanna, Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and 
direct impairment of its canonical function: implic ations for the therapeutic potential of lacosamide.  Mol 
Neurobiol, 2015. 51(2): p. 599-609. 
16. Krishnan-Sarin, S., S.S. O'Malley, N. Franco, D.A. Cavallo, M. Morean, J. Shi, B. Pittman, and J.H. Krystal, N-
methyl-D-aspartate receptor antagonism has differential effects on alcohol cr aving and drinking in heavy drinkers.  
Alcohol Clin Exp Res, 2015. 39(2): p. 300-7. 
17. Leeman, R.F., W.R. Corbin, C. Nogueira, S. Kri shnan-Sarin, M.N. Potenza, and S.S. O'Malley, A human alcohol 
self-administration paradigm to model individual differences in impaired control over alcohol use.  Exp Clin 
Psychopharmacol, 2013. 21(4): p. 303-14. 
18. O'Malley S.S., K.-S., S., Farren, C., Sinha, R., Kreek, M.J., Naltrexone decreases craving and alcohol self-
administration in alcohol-dependent subjects and acti vates the hypothalamo-pituitary-adrenocortical axis.  
Psychopharmacology, 2002. 160(1): p. 19-29. 
19. Krishnan-Sarin, S., Krystal, J.H., Shi, J., Pittman, B., O'Malley, S.S., Family history of alcoholism influences 
naltrexone-induced reduction in alcohol drinking.  Biological Psychiatry, 2007. 62: p. 694-697. 
20. Krishnan-Sarin, S., Cavallo, D., Shi, J., Franco, N., Pittman, B., O'Malley, S., et al., Memantine effects on human 
ethanol consumption: Initial impressions.  Alcoholism: Clinical and Experimental Research, 2009a. 33(6s): p. 
290A. 
21. McKee, S.A., O'Malley, S.S., Shi, J., Mase, T., Krishnan-Sarin, S., Effect of transdermal nicotine replacement on 
alcohol responses and alcohol self-administration.  Psychopharmacology 2008. 196(2): p. 189-200. 
22. McKee, S.A., Harrison, E.L., O'Malley, S.S., Krishnan-Sarin, S., Shi, J., Tetrault, J.M., Picciotto, M.R., Petrakis, I.L., 
Estevez, I.L., Balchunas, E., Varenicline reduces alcohol self-administration in heavy-drinking smokers.  Biological 
Psychiatry, 2009. 66(2): p. 185-90. 
23. Anton, R.F., Drobes, D.J., Voronin, K., Durazo-Avizu, R., Moak, D., Naltrexone effects on alcohol consumption in a 
clinical laboratory paradigm: temporal effects of drinking.  Psychopharmacology, 2004. 173: p. 32-40. 
24. Anton, R.F., Voronin, K.K., Rand all, P.K., Myrick, H., Tiffany, A., Naltrexone modification of drinking effects in a 
sub-acute treatment and bar-lab paradigm: Influence of OPRM1 and dopamine transporter (SCL6A3) genes.  
Alcohol Clin Exp Res, 2012. 36(11): p. 2000-2007. 
25. Drobes, D.J., Anton, R.F., Thomas, S.E., Voronin, K.A., A clinical laboratory paradigm for evaluating medication 
effects on alcohol consumption: naltrexone and nalmefene.  Neuropsychopharmacology, 2003. 28(4): p. 755-64. 
26. Myrick, H., Anton, R., Voronin, K., Wang, W., Henderson, S., A double-blind evaluation of gabapentin on alcohol 
effects and drinking in a clinical laboratory paradigm.  Alcoholism: Clinical and Experimental Research, 2007. 
31(2): p. 221-227. 
27. Myrick, H., Xingbao, L., Randall, P.K., Henderson, S., Voronin, K., Anton, R.F., The effect of aripiprazole on cue-
induced brain activation and drinking parameters in alcoholics.  J Clin Psychopharmacol, 2010. 30(4): p. 365-372. 
20¬†
¬†28. Haass-Koffler, C.L., L. Leggio, and G.A. Kenna, Pharmacological approaches to redu cing craving in patients with 
alcohol use disorders.  CNS Drugs, 2014. 28(4): p. 343-60. 
29. Camchong, J., M. Endres, and G. Fein, Decision making, risky behavior, and alcoholism.  Handb Clin Neurol, 2014. 
125: p. 227-36. 
30. den Uyl, T.E., T.E. Gladwin, M. Ri nck, J. Lindenmeyer, and R.W. Wiers, A clinical trial with combined transcranial 
direct current stimulation and alcohol approach bias retraining.  Addict Biol, 2016. 
31. Sharbanee, J.M., W.G. Stritzke, M.E. Jamalludin, and R.W. Wiers, Approach-alcohol action tendencies can be 
inhibited by cognitive load.  Psychopharmacology (Berl), 2014. 231(5): p. 967-75. 
32. Wiers, C.E., V.U. Ludwig, T.E. Gladwi n, S.Q. Park, A. Heinz, R.W. Wiers, M.  Rinck, J. Lindenmeyer, H. Walter, and 
F. Bermpohl, Effects of cognitive bias modification training on ne ural signatures of alcohol approach tendencies in 
male alcohol-dependent patients.  Addict Biol, 2015. 20(5): p. 990-9. 
33. Wiers, C.E., C. Stelzel, T.E. Gladwin, S.Q. Park, S. Pa welczack, C.K. Gawron, H. Stuke,  A. Heinz, R.W. Wiers, M. 
Rinck, J. Lindenmeyer, H. Walter, and F. Bermpohl, Effects of cognitive bias modification training on neural 
alcohol cue reactivity in alcohol dependence.  Am J Psychiatry, 2015. 172(4): p. 335-43. 
34. Heinz, A.J., D.L. Pennington, N.  Cohen, B. Schmeling, B.A. Lash er, E. Schrodek, and S.L. Batki, Relations Between 
Cognitive Functioning and Alcohol Use, Craving, and Post-Traumatic Stress: An Examination Among Trauma-
Exposed Military Veterans With Alcohol Use Disorder.  Mil Med, 2016. 181(7): p. 663-71     PMC4940120  
36. van Harten, J., Stevens, L.A., Raghoebar, M., Holland, R.L., Wesnes, K., Coumot, A., Fluvoxamine does not 
interact with alcohol or potentiate alcoho l-related impairment of cognitive function.  Clin Pharmacol Ther, 1992. 
52(4): p. 427-35. 
37. Wesnes, K.A., Garratt, C., Wick ens, M., Gudgeon, A., Oliver, S., Effects of sibutramine alone and with alcohol on 
cognitive function in healthy volunteers.  Br J Clin Pharmacol, 2000. 49: p. 110-117. 
38. Beyreuther, B.K., J. Freitag, C. Heers, N. Krebsfanger, U. Scharfenecker, and T. Stohr, Lacosamide: a review of 
preclinical properties.  CNS Drug Rev, 2007. 13 (1): p. 21-42. 
39. Patyar, S. and B. Medhi, Lacosamide, a newer antiepileptic.  Neurosciences (Riyadh), 2010. 15(1): p. 3-6. 
40. Saussele, T., [Lacosamide. A new antiepileptic drug as adjunctive  therapy in patients with partial-onset seizures].  
Med Monatsschr Pharm, 2008. 31 (10): p. 374-7. 
41. Bouchery, E.E., H.J. Harwood, J.J. Sacks, C.J. Simon, and R.D. Brewer, Economic costs of excessive alcohol 
consumption in the U.S., 2006.  American journal of preventive medicine, 2011. 41(5): p. 516-24. 
42. CDC, Excessive Drinking Costs U.S. $223.5 Billion . 2014, Center for Disease Control: Atlanta, GA. 
43. SAMHSA, CBHSQ, Key substance use and mental health indicators in the United States: Results from the 2015 
National Survey on Drug Use and Health.  Retrieved from http://www.samhsa. gov/data/, 2016. (HHS Publication 
No. SMA 16-4984, NSDUH Series H-51). 
44. Grant, B.F., R.B. Goldstein, T.D. Saha, S.P. Chou, J. Ju ng, H. Zhang, R.P. Pickering,  W.J. Ruan, S.M. Smith, B. 
Huang, and D.S. Hasin, Epidemiology of DSM-5 Alcohol Use Disorder : Results from the Na tional Epidemiologic 
Survey on Alcohol and Related Conditions III.  JAMA Psychiatry, 2015. 72(8): p. 757-66. 
45. Rubinsky, A.D., C. Chen, S.L. Ba tki, E.C. Williams, and A.H. Harris, Comparative utilization of pharmacotherapy for 
alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual 
diagnoses.  J Psychiatr Res, 2015. 69: p. 150-7.  PMID: 26343607 
46. Hopf, F.W. and H.M. Lesscher, Rodent models for comp ulsive alcohol intake.  Alcohol, 2014. 48(3): p. 253-64. 
47. Sanchis-Segura, C. and R. Spanagel, Behavioural assessment of drug rein forcement and addictive features in 
rodents: an overview.  Addict Biol, 2006. 11(1): p. 2-38. 
48. Buffington, S.A., W. Huan g, and M. Costa-Mattioli, Translational control in synaptic plasticity and cognitive 
dysfunction.  Annu Rev Neurosci, 2014. 37: p. 17-38. 
54. Hamid, A.A., J.R. Pettibone, O.S. Mabrouk, V.L. Hetr ick, R. Schmidt, C.M. Vander Weele, R.T. Kennedy, B.J. 
Aragona, and J.D. Berke, Mesolimbic dopamine signals the value of work.  Nat Neurosci, 2016. 19(1): p. 117-26. 
55. Mallet, N., R. Schmidt, D. Leventhal, F. Chen, N. Amer, T. Boraud, and J.D. Berke, Arkypallidal Cells Send a Stop 
Signal to Striatum.  Neuron, 2016. 89(2): p. 308-16. 
56. Schmidt, R., D.K. Leventhal, N.  Mallet, F. Chen, and J.D. Berke, Canceling actions involves a race between basal 
ganglia pathways.  Nat Neurosci, 2013. 16(8): p. 1118-24. 
57. Batki, S.L., L. Leontieva, J.A. Dimmock, and R. Ploutz-Snyder, Negative symptoms are associated with less alcohol 
use, craving, and "high" in alcohol dependent patients with schizophrenia.  Schizophr Res, 2008. 105(1-3): p. 
201-7. 
58. Batki, S.L., D.L. Pennington, B. Lasher, T.C. Neylan, T. Metzler, A. Waldrop, K. Delucchi, and E. Herbst, 
Topiramate treatment of alcohol use disorder in vetera ns with posttraumatic stre ss disorder: a randomized 
controlled pilot trial.  Alcohol Clin Exp Res, 2014. 38(8): p. 2169-77     PMC4146719  
21¬†
¬†59. Batki, S.L., What is the right pharmacotherapy for alcohol use disorder in patients with schizophrenia?  J Clin 
Psychiatry, 2015. 76(10): p. e1336-7. PMID: 26528663 
60. Wiers, R.W., Rinck, M., Dictus, M., van den Wildenberg, E., Relatively strong automatic appetitive action 
tendencies in male carriers of the OPRM1 G-allele.  Genes, brain, and behavior, 2009. 8 (1): p. 101-106. 
61. Rinck, M., Becker, E.S., Approach and avoidance in fear of spiders.  J Behav Ther Exp Psychiatry, 2007. 38(2): p. 
105-120. 
62. Bohn, M.J., Krahn, D.D., Staehler, B.A., Development and initial validation of a measure of drinking urges in 
abstinent alcoholics.  Alcoholism: Clinical and Experimental Research, 1995. 19: p. 600-606. 
63. Crews, F.T. an d C.A. Boettiger, Impulsivity, frontal lobes and risk for addiction.  Pharmacol Biochem Behav, 2009. 
93(3): p. 237-47. 
64. Claus, E.D. an d K.E. Hutchison, Neural mechanisms of risk taking and relationships with hazardous drinking.  
Alcohol Clin Exp Res, 2012. 36(6): p. 932-40. 
65. Yarosh, H.L., C.J. Hyatt, S.A. Meda, R. Jianto nio-Kelly, M.N. Potenza, M. Assaf, and D.P. G, Relationships between 
reward sensitivity, risk-taking and family history of al coholism during an interactive competitive fMRI task.  PLoS 
One, 2014. 9(2): p. e88188. 
66. Ashenhurst, J.R., M. Seaman, and J.D. Jentsch, Responding in a test of decision-making under risk is under 
moderate genetic control in the rat.  Alcohol Clin Exp Res, 2012. 36(6): p. 941-9. 
67. Lejuez, C.W., Read, J.P., Kahler, C.W., Richards, J.B., Ramsey, S.E., Stuart, G.L. et al., Evaluation of a behavioral 
measure of risk taking: the Ball oon Analogue Risk Task (BART).  Journal of Experimental Psychology Applied, 
2002. 8: p. 75-84. 
68. Lejuez, C.W., Aklin, W.M., Zv olensky, M.J., Pedulla, C.M., Evaluation of the Balloon Analogue Risk Task (BART) as 
a predictor of adolescent real-world risk-taking behaviors.  Journal of Adolescence, 2003. 26(4): p. 475-479. 
69. Bickel, W.K., Miller, M.L., Yi, R., Kowa l, B.P., Lindquist, D.M., Pitcock, J.A., Behavioral and neuroeconomics of 
drug addiction: Competing neural syst ems and temporal di scounting processes.  Drug Alcohol Depend., 2007. 
90(Suppl 1): p. S85-91. 
70. Baker, F., Johnson, M., Bickel, W., Delay discounting in current and never-be fore cigarette smokers: Similarities 
and differences across commodity, sign, and magnitude.  Journal of Abnormal Psychology, 2003. 112(3): p. 382-
392. 
71. Bickel, W.K., Odum, A.L., Madden, G.J., Impulsivity and cigarette smoking: De lay discounting in current, never, 
and ex-smokers.  Psychopharmacology  1999. 146 : p. 447-454. 
72. Coffey, S., Gudleski, G., Saladin, M., Brady, K., Impulsivity and rapid discounting of delayed hypothetical rewards 
in cocaine-dependent individuals.  Experimental and Clinical Psychopharmacology, 2003. 11(1): p. 18-25. 
73. Kirby, K., Petry, N., Bickel, W., Heroin addicts have higher discount rates for delayed rewards than non-drug-
using controls.  Journal of Experimental Psychology General, 1999. 128: p. 78-87. 
74. Ijff, D.M., van Veenendaal, T.M., Majoie, H.J., de Louw, A.J., Jansen, J.F., Aldenkamp, A.P. , Cognitive effects of 
lacosamide as adjunctive therapy in refractory epilepsy.  Acta Neurol Scand, 2015. 131(6): p. 347-54. 
75. Becker, G.S., Murphy, K.M., A theory of rational addiction.  Journal of Political Economy, 1988. 96(4): p. 675-700. 
76. Griffiths, R.R., Troisi, J. R. II, Silvermian, K., Miumford, G. K. , Multiple choice procedure: An efficient approach 
for investigating drug reinforcement in humans.  Behavioural Pharmacology, 1993. 4: p. 3-13. 
77. Sobell, L.C., & Sobell, M. B., Timeline follow-back: a technique for asse ssing self-reported ethanol consumption.  
Measuring Alcohol Consumption: Psychosocial and Biochemical Methods, 1992. J. Alle n and R.Z. Litten. Totowa, 
NJ, Humana Press, Inc.: 41-72. 
78. Liu, R.J., C. Duman, T. Kato, B. Hare, D. Lopresto, E. Bang, J. Burgdorf, J. Moskal, J. Taylor, G. Aghajanian, and 
R.S. Duman, GLYX-13 Produces Rapid Antidepressant Response s with Key Synaptic and Behavioral Effects 
Distinct from Ketamine.  Neuropsychopharmacology, 2016. 
80. Sankoh, A.J., M.F. Huque, and S.D. Dubey, Some comments on frequently used multiple endpoint adjustment 
methods in clinical trials.  Stat Med, 1997. 16(22): p. 2529-42. 
81. Martin, S., Earlywine, M., Musty, R.E., Perrine, M.W., Swift, R.M., Development and validation of the Biphasic 
Alcohol Effects Scale.  Alcoholism: Clinical and Experimental Research, 1993. 17: p. 140-146. 
82. Barak, S., F. Liu, S.B. Hami da, Q.V. Yowell, J. Ne asta, V. Kharazia, P.H.  Janak, and D. Ron, Disruption of alcohol-
related memories by mTORC1 inhibition prevents relapse.  Nature Neuroscience, 2013. 16(8): p. 1111-1117 
PMCID: 3725202. 
84. Levine, J.S., N.R., SAFTEE: A technique for the systematic assessment of side effects in clinical trials.  
Psychopharmacology Bulletin, 1986. 22 : p. 343-381. 
85. National Advisory Council on Alcohol Abuse and Alco holism. (2005). Recommended council guidelines on ethyl 
alcohol administration in human experimentation. NIAAA.  Retrieved from =. Accessed 12/1/16.  
22¬†
¬†86. Watson, T.E., Total body water and alcohol le vels: Updating the fundamentals , in Human Metabolism of Alcohol , 
K.E.K.R.D. Batt, Editor. 1989, CR C Press: Florida. p. 44-66. 
87. Sinha, R., Catapano, D., O'Malley, S.S., Stress reactivity and stress-induced cocaine craving.  Paper presented at 
the Annual Meetings of the College on Problems of Drug Dependence, Nashville, TN, 1997, June 12-17. 
88. Miller, W.R., Zweben, A., DiCl emente, C.C., Rychtarik, R.G., Motivational Enhancement Therapy manual: A clinical 
research guide for therapists treating individuals with alcohol abuse and dependence.  National Institute on 
Alcohol Abuse and Alcoholism, Rockville, MD, 1992. 
89. (U.S.), N.I.A.A.A., Rethinking drinking alcohol and your health: re search-based information from the National 
Institutes of Health, U.S. Department of Health and Human Services , NIAAA, Editor. 2009, National Institute on 
Alcohol Abuse and Alcoholism: Bethesda, MD. 
90. Bureau, U.S.C., 2010 Census Interactive Population Search: CA - San Francisco city , in U.S. Census Bureau . 2010. 
91. UCB, I., Full Prescribing Information for Vimpat ¬Æ (lacosamide).  2014. 
93. Sellers, E.M., et al., Characterization of DSM-III-R criteria for unc omplicated alcohol withdrawal provides an 
empirical basis for DSM-IV.  Arch Gen Psychiatry, 1991. 48(5): p. 442-447. 
94. Claasen, C., Adinoff, B., Alcohol Withdrawal Syndrome: Guidelines for Management.  CNS Drugs, 1999. 12(4): p. 
279. 
95. Michelhaugh, S.K., Basha, M., Rhoney, D.H., Shah, A.K., Mittal, S., Acute or chronic use of lacosamide does not 
alter its distribution between serum and cerebrospinal fluid.  Epilepsia, 2015. 56(11): p. 1732-7. 
96. First, M.B., Williams, J.B.W ., Karg, R.S., Spitzer, R.L., Structured Clinical Interview for DSM-5, Research Version 
(SCID-5, Research Version; SCID-5-RV). Arlington, VA,.  American Psychiatric Association, 2015. 
97. Saunders, J.B., Aasland, O.G., Babor, T.F., de la Fuente, J.R., Grant, M., Development of the Alcohol Use 
Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful 
Alcohol Consumption -- II.  Addiction, 1993. 88: p. 791-804. 
98. Patton, J.H., Stanford, M. S., Barratt, E. S. , Factor structure of the Barratt Impulsiveness Scale.  Journal of Clinical 
Psychology, 1995. 51: p. 768-774. 
99. Inc., I., Alco-Sensor IV with memory: features  and benefits. [Commercial website]. 
100. Bujarski, S., Ray, L.A..  Experimental psychopathology paradigms fo r alcohol use disorders: Applications for 
translational research.   Behav Res Ther, 2016.  86: p.11-22.  
101. Posner, K., Brown, G.K., Stanley, B., Brent, D.A., Yershova, K.V., Oquendo, M.A. , Currier, G.W., Melvin, G.A., 
Greenhill, L., Shen, S., Mann, J.J. The Columbia-Suicide Severity Rating Scale: initial validity and internal 
consistency findings from three multisit e studies with adolescents and adults . Am J Psychiatry. 2011. 168: 
p.1266-77. 
 